 
 
Making Friends with Yourself: A Depression Prevention Program for 
Adolescents 
 
 
 
NCT number  [STUDY_ID_REMOVED] 
Document Date  03/01/[ADDRESS_116677] Page 1 of 147  version 1.1  
01 March 2021 
 
 
STUDY PROTOCOL  
Making Friends With Yourself: A Depression Prevention 
Program For Adolescents 
Short Name : [CONTACT_100359] S.M.A.R.T. Project :  Stress Management and Resilience Training for Teens   
UNC Program on Integrative Medicine 
UNC Department of Physical Medicine & Rehabilitation 
Email: [EMAIL_2060] | Phone: ([PHONE_2405] 
 
Master Protocol 
S.M.A.R.T. Project Page 2 of 147  version 1.1  
01 March 2021 
 STUDY PROTOCOL 
Making Friends with Yourself: A Depression Prevention 
Program for Adolescents 
Short Name: [CONTACT_100359] S.M.A.R.T. Project: Stress Management and Resilience Training for Teens 
A trial designed to refine and feasibility-test a mindfulness-based self-compassion intervention and an 
attention-control intervention with 80 adolescents with subsyndromal depression.  
Principal Investigator:  
[INVESTIGATOR_105057], PhD 
Director of the UNC Program on Integrative Medicine, Associate Professor, Department of 
Physical Medicine & Rehabilitation  
Supported by:  
[CONTACT_105103]: 1 R34 AT008822-01A1  
Study Intervention Provided by:  
[CONTACT_105104] (IDE):  
Not applicable  
 
 
 
 
 
 
 
 
 
  
Master Protocol 
S.M.A.R.T. Project Page 3 of 147  version 1.1  
01 March 2021 
 TOOL REVISION HISTORY 
Version 1.1 
Version Date:  1 March 2021 
Summary of Revisions Made:    
 The PROMIS Pediatric Depression Scale was used as the measure in the time-to-event analysis 
because it was collected weekly rather than only 5 times at irregular intervals like the SMFQ.  
 Christine Lathren added as a Research Associate to supervise the Project Manager. 
 
Version 1.0 
Version Date:  3 January 2020 
Summary of Revisions Made:    
 Section __: Inclusion/Exclusion 
a. Removed lower limit for QIDS due to QIDS, DISC-IV, clinical assessment, SMFQ, and 
PROMIS not all measuring the same levels of depression. 
 The team decided not to hold an orientation session, so as to reduce burden on the parents and 
adolescent participants. The content of the control group curricula was updated.  Study Pages 
site was added. The name [CONTACT_105156]. The two programs will be described as 
two different programs to reduce stress and enhance well-being in high school students. 
Updated consents and measures are added. 
 Changes to the Safety Plan necessitated an update to the protocol. Chloe Brown is added as a 
research assistant. 
 
Version 0.1 
Version Date: 1 July 2015 
Summary of Revisions Made:  
 Initial master protocol 
 
 
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116678] Manager, Study Coordinator, and Research Assistants ................ Error! Bookmark not defined.  
Consultants ................................................................................................ Error! Bookmark not defined.  
PARTICIPATING STUDY SITES ............................................................................................................ 11  
PRÉCIS ............................................................................................................................................. 11  
Study Title ............................................................................................................................................... 11 
Objectives ............................................................................................................................................... 11 
Design and Outcomes ............................................................................................................................. 11 
Interventions and Duration .................................................................................................................... 11 
Sample Size and Population ................................................................................................................... 12 
1. STUDY OBJECTIVES ....................................................................................................................... 12  
1.1: Primary Objective ............................................................................................................................ 12 
Specific Aim 1  ..................................................................................................................................... 12 
1.2: Secondary Objectives ...................................................................................................................... 12 
Specific Aim 2  ..................................................................................................................................... 12 
Specific Aim 3  ..................................................................................................................................... 13 
2. BACKGROUND AND RATIONALE ................................................................................................... 13  
2.1: Background on Condition, Primary Study Focus ............................................................................. 13 
2.2: Study Rationale ................................................................................................................................ [ADDRESS_116679] Page 5 of 147  version 1.1  
01 March 2021 
 Changes in Adolescence and the Onset of Depression.  ................................................................... 14 
Theoretical Explanations for Depression and Mechanisms of Change ............................................ 14 
Behavioral Programs for Depression Prevention in Adolescents  .................................................... 15 
Mindfulness-based Self-Compassion: An Antidote for Depression?  ............................................... 15 
Development of a Mindfulness-based Self-Compassion Program for Adolescents with 
Subsyndromal Depression: “Making Friends with Yourself”  ........................................................... 16 
Rationale for use of an active comparison group as an attention control  ...................................... 17 
Preliminary Studies  ............................................................................................................................ 17 
3. STUDY DESIGN ............................................................................................................................. 19  
3.1: Recruitment, screening and consent ............................................................................................... 20 
Recruitment ....................................................................................................................................... 20 
Screening  ............................................................................................................................................ 20 
4. Selection and Enrollment of Participants ....................................................................................... 21  
4.1: Inclusion Criteria .............................................................................................................................. 21 
4.2: Exclusion Criteria ............................................................................................................................. 22 
4.3: Study Enrollment Procedures .......................................................................................................... 22 
4.3.1: Phone Screening and Psychological Exam  .............................................................................. 23 
4.3.2: Consenting  ............................................................................................................................... 23 
4.3.3: Documentation  ........................................................................................................................ 23 
4.3.4: Randomization ......................................................................................................................... 23 
5. STUDY INTERVENTIONS ................................................................................................................ 23  
5.1: Interventions, Administration, and Duration .................................................................................. 23 
5.1.1: Prevention Programs  ............................................................................................................... 23 
5.1.2: Measurement Time Points  ...................................................................................................... 25 
5.1.3: Measures  ................................................................................................................................. [ADDRESS_116680] Two Cohorts ........................................................................................... 29 
5.2: Handling of Study Interventions ...................................................................................................... 29 
5.2.1: Masking ........................................................................................................................................ 29 
5.3: Concomitant Interventions .............................................................................................................. 29 
5.3.1: Allowable Interventions ............................................................................................................... [ADDRESS_116681] Page 6 of 147  version 1.1  
01 March 2021 
 5.3.2: Required Interventions ................................................................................................................. 29 
5.3.3: Prohibited Interventions .............................................................................................................. 30 
5.4: Adherence Assessment ................................................................................................................... 30 
6. STUDY PROCEDURES .................................................................................................................... 30  
6.1: Schedule of Evaluations ................................................................................................................... 30 
6.2: Description of Evaluations ............................................................................................................... 30 
6.2.1  Screening Evaluation  .......................................................................................................... 30 
6.2.2: Enrollment, Baseline, and/or Randomization .......................................................................... 31 
6.2.3: Follow-up Visits ........................................................................................................................ 31 
6.2.5: Completion/Final Evaluation .................................................................................................... 32 
7. SAFETY ASSESSMENTS .................................................................................................................. 33  
7.1: Specification of Safety Parameters .................................................................................................. 33 
7.2: Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters ......................... 33 
7.3: Adverse Events and Serious Adverse Events ................................................................................... 33 
7.3.1: Definitions  ............................................................................................................................... 33 
7.3.2: Classification of AE Severity  .................................................................................................... 34 
7.3.3: AE Attribution Scale  ................................................................................................................ 34 
7.4: Reporting Procedures ...................................................................................................................... 34 
Detection of increased depression.  .................................................................................................. 36 
7.5: Follow-up for Adverse Events .......................................................................................................... 36 
7.6: Safety Monitoring (See DSMP) ........................................................................................................ 36 
7.6.1: Frequency of Review  ............................................................................................................... 36 
7.6.2: Review Materials  ..................................................................................................................... 36 
7.6.3: Summary report  ...................................................................................................................... 37 
8. INTERVENTION DISCONTINUATION............................................................................................... 37  
8.1:  Discontinuation of Intervention for a Participant .......................................................................... 37 
8.2: Possible reasons for discontinuation of the whole study ............................................................... 37 
8.3: Early discontinuation ....................................................................................................................... 37 
8.4: Normal end to the study ................................................................................................................. [ADDRESS_116682] Page 7 of 147  version 1.1  
01 March 2021 
 9.1: General Design Issues ...................................................................................................................... 37 
9.2: Sample Size and Randomization ...................................................................................................... 38 
9.2.1: Treatment Assignment Procedures  ........................................................................................ 38 
9.3: Definition of Populations ................................................................................................................. 38 
9.4: Interim Analyses and Stoppi[INVESTIGATOR_1869] .............................................................................................. 38 
9.4.1: Study-wide stoppi[INVESTIGATOR_004]  ...................................................................................................... 38 
9.4.2: Individual stoppi[INVESTIGATOR_004]  ......................................................................................................... 38 
9.4.3: Additional Reasons for Withdrawal of a Participant  ............................................................. 39 
9.5: Outcomes ........................................................................................................................................ 39 
9.5.1: Primary Outcome  ................................................................................................................... 39 
9.5.2: Secondary Outcomes ............................................................................................................... 39 
9.6: Data Analyses .................................................................................................................................. 40 
9.6.1 Exploratory analyses of outcomes and mediators.  ................................................................. 40 
9.6.2:  Feasibility Analyses  ................................................................................................................ 40 
10. DATA COLLECTION AND QUALITY ASSURANCE ............................................................................ 42  
10.1: Data Collection: Data Type, Personnel Collecting Data ................................................................. 42 
10.2: Data Management ......................................................................................................................... 42 
10.3: Quality Assurance .......................................................................................................................... 42 
10.3.1: Training  .................................................................................................................................. 42 
10.3.2: Quality Control Committee  ................................................................................................... 43 
10.3.3: Metrics  ................................................................................................................................... 43 
10.3.4: Protocol Deviations  ............................................................................................................... 43 
10.3.5: Monitoring  ............................................................................................................................. 43 
11. PARTICIPANT RIGHTS AND CONFIDENTIALITY .............................................................................. 44  
11.1: Institutional Review Board (IRB) Review ....................................................................................... 44 
11.2: Informed Consent Forms ............................................................................................................... 44 
11.3: Participant Confidentiality ............................................................................................................. 44 
11.4: Study Discontinuation ................................................................................................................... 44 
12. COMMITTEES ............................................................................................................................. 44  
13. PUBLICATION OF RESEARCH FINDINGS ................................................ Error! Bookmark not defined. 
Master Protocol 
S.M.A.R.T. Project Page 8 of 147  version 1.1  
01 March 2021 
 14. REFERENCES ............................................................................................................................... 44  
Appendices ...................................................................................................................................... 55  
Appendix I.a: Phone Consent (version 0.3, 7 June 2017) ....................................................................... 56 
Appendix I.b: Parent Consent (version 0.3, 1 June 2017) ...................................................................... 61 
Appendix I.c: Child Assent (ages 14-17) (version 0.3, 1 June 2017) ....................................................... 64 
Appendix I.d: Adult Consent (version 0.3, 1 June 2017)......................................................................... 67 
Appendix II.a: QIDS-SR ............................................................................................................................ 70 
Appendix II.b: Diagnostic Interview Schedule for Children- Version IV (DISC-IV) .................................. 74 
Appendix II.c: Adolescent Survey Measures ......................................................................................... 102 
Short Mood and Feelings Questionnaire (SMFQ-C) ......................................................................... 102 
Brief Resiliency Scale (BRS) .............................................................................................................. 103 
Adolescent Cognitive Style Questionnaire (ACSQ) ........................................................................... 104 
Ruminative Response Style scale-brooding factor (RRS-B) .............................................................. [ADDRESS_116683] for Adolescents (TOSCA-A) ............................................................... 111 
Self-Compassion Scale (SCS) ............................................................................................................. 117 
Child and Adolescent Mindfulness Measure (CAMM) ..................................................................... 119 
Adolescent Demographic Questions ................................................................................................ 120 
Appendix II.d: Parent Survey ................................................................................................................ 121 
Short Mood and Feelings Questionnaire (SMFQ-P) ......................................................................... 121 
Parent Demographics Questions ...................................................................................................... 122 
Appendix II.e: PROMIS Pediatric Short Form (version 1.1) .................................................................. 125 
Appendix II.f: Expectation of Benefit / Credibility ................................................................................ 126 
Appendix II.g: Daily Diary ...................................................................................................................... 127 
Appendix III: Recruitment ..................................................................................................................... 128 
Flyer .................................................................................................................................................. 128 
Email Announcement ....................................................................................................................... 129 
Appendix IV: Data Safety Monitoring Plan (version 0.3, 23 May 2017) ............................................... [ADDRESS_116684] Page 10 of 147  version 1.1  
01 March 2021 
 STUDY TEAM ROSTER  
Principal Investigator 
 Susan A. Gaylord, PI,  Department of Physical Medicine and Rehabilitation, 183 Wing D, 
C.B.#7200, [ADDRESS_116685], UNC School of Medicine, Chapel Hill, N.C.  [ZIP_CODE]. Phone: 
[PHONE_2406], email:   [EMAIL_2061]  
Co-Investigators 
 Keturah R. Faurot, Co-I,  Department of Physical Medicine and Rehabilitation, 173 Wing D, 
C.B.#7200, [ADDRESS_116686], UNC School of Medicine, Chapel Hill, N.C.  [ZIP_CODE]. Phone: 
[PHONE_2406], email:   [EMAIL_2062]  
 Chirayath M. Suchindran, Co-I, Department of Biostatistics , CB # 7420, 3103-A, McGavran-
Greenberg Hall,  Gillings School of Global Public Health, Chapel Hill, NC [ZIP_CODE]. Phone: 919-
966-7258, Fax: [PHONE_2407], email: [EMAIL_2063] 
Project Manager, Study Coordinator, and Research Assistants 
 Nandie Elhadidy, Research Assistant, Project Manager as of June 19th, 2020  Department of 
Physical Medicine and Rehabilitation, 184 Wing D, C.B.#7200, [ADDRESS_116687], UNC School of 
Medicine, Chapel Hill, N.C.  [ZIP_CODE]. Phone: [PHONE_2406], email: [EMAIL_2064]   
 Chanee Lynch, Project Manager until June 18, 2020, Department of Physical Medicine and 
Rehabilitation, 183 Wing D, C.B.#7200, [ADDRESS_116688], UNC School of Medicine, Chapel Hill, 
N.C.  [ZIP_CODE]. Phone: [PHONE_2406], email:   [EMAIL_2065]  
 Christine Lathren, Research Associate,  Department of Physical Medicine and Rehabilitation, 184 
Wing D, C.B.#7200, [ADDRESS_116689], UNC School of Medicine, Chapel Hill, N.C.  [ZIP_CODE]. 
Phone: [PHONE_2406], email: [EMAIL_2064]   
Consultants 
 John F. Curry, Co-I, Department of Psychology and Neuroscience, Box [ZIP_CODE], [ADDRESS_116690], 
Duke University, Durham, NC [ZIP_CODE]. Duke University, Durham, NC. Phone: (919) 681-
0020, email: [EMAIL_2066]   
 April Harris-Britt, Co-I, AHB Center for Behavioral Health and Wellness, [ADDRESS_116691], Suite D, Durham, North Carolina [ZIP_CODE] 
([PHONE_2408] x1001 Email: [EMAIL_2067]   
 
 
  
Master Protocol 
S.M.A.R.T. Project Page 11 of 147  version 1.1  
01 March 2021 
 PARTICIPATING STUDY SITES 
Primary Site : University of North Carolina, School of Medicine and Health Care System, [ADDRESS_116692], Chapel Hill, North Carolina, [ZIP_CODE].  
PRÉCIS  
Study Title  
Making Friends with Yourself: A Depression Prevention Program for Adolescents (aka The S.M.A.R.T. 
Project: Stress Management and Resilience Training for Teens)  
Objectives  
The primary objective of this research project is to refine, manualize, and test the feasibility of the a 
mindfulness-based self-compassion program and an attention control program focused on developi[INVESTIGATOR_105058] (e.g., exercise, healthy food choices, sleep 
hygiene, relationship skills) for 14-[ADDRESS_116693] the feasibility of randomizing participants to the two educational 
programs. Results will guide the development of an adequately powered clinical trial in terms of 
recruitment needs and logistics; subjects’ acceptance of the treatment and control programs; 
equivalence of the credibility of the two programs; and subjects’ willingness to complete assessment 
instruments, adhere to study protocols, and complete the study.    
Another secondary objective is to explore primary and secondary outcomes and mediators in response 
to the mindfulness-based program, including incident depression (primary outcome), change in 
depressive symptoms and resilience (secondary outcomes) and rumination, negative cognitive style, and 
shame (potential mediators). 
Design and Outcomes   
Four cohorts of adolescents, each with 20 participants, will be recruited. In each cohort, twenty 
individuals will be randomized with 10 each in the mindful self-compassion group (Making Friends with 
Yourself) and the healthy behavior skills group. In addition, each adolescent will be accompanied by a 
parent (n=80).  Adolescents complete brief weekly questionnaires to assess depressive symptoms as 
well as a longer set of online questionnaires at baseline, weeks [ADDRESS_116694]-
intervention. 
Interventions and Duration  
Both education intervention groups meet once a week for 1 hour and 45 minutes for 8 weeks. After 
completion of the program, there will be monthly sessions in the continuation phase (90 minutes per 
session) for [ADDRESS_116695] Page 12 of 147  version 1.1  
01 March 2021 
 Sample Size and Population  
The sample will include 80 adolescent high school students with subsyndromal depression, defined as 
having symptoms of major depression that are not of sufficient severity to meet diagnostic criteria of 
major depression disorder (MDD).  
1. STUDY OBJECTIVES 
1.1: Primary Objective 
The primary goal of this research project is to refine and test the feasibility of the “Making Friends with 
Yourself” program, as well as a credible attention control program, involving education and discussion 
on healthy behaviors, for 14-17 year-old adolescents with subsyndromal depression and to compare the 
feasibility of the two interventions1.  
The proposed study will randomize high school aged adolescents (aged 14-17, participants may turn 18 
after enrollment) with subsyndromal depression to an eight-week program of the proposed prevention 
program, entitled “Making Friends with Yourself” (MFY), or an attention-control group that focuses on 
healthy behaviors. 
Specific Aim 1  
Refine and manualize the mindful self-compassion program, “Making Friends with Yourself” (MFY), and 
a credible attention control program among adolescents. Refinement of procedure manuals for 
adolescent participants and instructors will ensure that future interventions are delivered in a consistent 
and reproducible fashion.  
Purpose 1 
Refinement of procedure manuals for adolescent participants and instructors will ensure that future 
interventions are delivered in a consistent and reproducible fashion. 
Our group has developed the MFY program as a developmentally-appropriate adaptation of Neff 
and Germer’s Mindful Self-compassion program. The MFY program has been pi[INVESTIGATOR_105059]. Further 
adaptation will target an adolescent population with subsyndromal depression.  
1.2: Secondary Objectives 
Specific Aim [ADDRESS_116696] the feasibility of an exploratory clinical trial involving a mindful self-compassion intervention, the 
MFY program (treatment group), and a comparison attention-control among 14-17 year old adolescents 
(participants may turn 18 after enrollment) with subsyndomal depression. Study results will guide the 
development of an adequately powered clinical trial in terms of recruitment needs and logistics, 
equivalence of credibility of the two programs, and participants’ willingness to complete assessment 
instruments, adhere to study protocols, and complete the study.    
Purpose 2 
Study results will guide the development of an adequately powered clinical trial in terms of 
recruitment needs and logistics; subjects’ acceptance of the treatment and control programs; 
Master Protocol 
S.M.A.R.T. Project Page 13 of 147  version 1.1  
01 March 2021 
 equivalence of credibility of the two programs; and subjects’ willingness to complete assessment 
instruments, adhere to study protocols, and complete the study.    
Specific Aim 3 
With feasibility being tested in Aim 2, we will explore primary and secondary outcomes and mediators in 
response to the MFY program in Aim 3, including time to incident depression by [CONTACT_35667] 36-week 
follow-up (i.e., MDD-major depressive disorder) (primary outcome); resilience, change in depressive 
symptoms (secondary outcomes); and rumination, negative cognitive style, and shame (potential 
mediators). 
Purpose 3   
This study intends to analyze, in an exploratory fashion, the following:  incident depression (primary 
outcome); change in depressive symptoms and resilience (secondary outcomes); and rumination, 
negative cognitive style, and shame (potential mediators). 
Measures are collected at baseline, halfway through the 8-week course, after completion of each 8-
week program, at [ADDRESS_116697]-program. Analyses are conducted 
to inform the planning of an adequately powered randomized controlled trial.   
2. BACKGROUND AND RATIONALE  
2.1: Background on Condition, Primary Study Focus 
The rate of depression increases markedly over the course of adolescence3. Currently 20-25% of 
adolescents experience a depressive epi[INVESTIGATOR_105060]. In 2012 alone, 14% of 
girls and 5% of boys age 12-[ADDRESS_116698] appears in 
adolescence and unsuccessful treatment of adolescent depression increases the risk of chronic or 
recurrent depression in adulthood, managing depression symptoms at this critical stage of development 
can benefit mental health and functioning throughout the lifespan9.    
2.2: Study Rationale  
The Impact of Depression in Adolescence 
Adolescents struggling with depression are often set on a maladaptive behavior trajectory which may 
lead to academic challenges, substance abuse, risky sexual behavior, impairment in relationship 
building, and suicidality30-34. They are also more likely to experience negative somatic health outcomes 
such as migraine headaches35 and obesity36. Depressive symptoms are associated with sleep 
disturbances (e.g. insomnia and hypersomnia), exacerbating the negative impacts on health and social 
domains37. These difficulties often persist into adulthood34,38,39. Adolescent depression was shown to 
predict poorer health, higher health-care utilization, low levels of social support, and increased work 
impairment due to physical health over the subsequent decade35,40. Adolescent depression may also 
result in an altered educational trajectory (i.e., droppi[INVESTIGATOR_105061], change of type of post-
secondary school) 41. Those who experienced even subsyndromal depression, defined as evidencing 
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116699] a 
higher risk of developi[INVESTIGATOR_105062] (MDD) as adolescents 43and are two to three times 
more likely to experience depression as adults39,44,45;  depression in adults has been associated with 
lower lifetime income and socioeconomic status, welfare dependency, and fewer occupation 
options33,46-48.   
Changes in Adolescence and the Onset of Depression 
During adolescence, individuals undergo rapid physiological growth49-51 including changes in both 
structure and function of the brain52. Coupled with these physiological changes are new cognitive 
abilities including the capacity for metacognition and the ability to think abstractly, which promote 
adolescents’ increasingly complex and sophisticated ways of relating to their world53. Taken together, 
such changes often have dramatic effects on the ways in which adolescents perceive, understand, and 
interpret their daily experiences, particularly those that occur in social and emotional domains. Identity 
exploration, characteristic of this stage of development54, may lead adolescents to self-reflect and to 
consider their relationship with others and their role in society. As they compare themselves with their 
peers, adolescents often engage in self-doubt and self-criticism55, which may contribute to a negative 
self-image and self-consciousness56,57. Additionally, due to these physical and cognitive changes, 
reflected in peer evaluation and greater awareness of gender roles, adolescents often experience 
increased shame58,, as well as increased stress and poor copi[INVESTIGATOR_25110]. 
Theoretical Explanations for Depression and Mechanisms of Change  
Theoretical underpi[INVESTIGATOR_105063], and 
specifically negative 
cognitive style , predicts 
depression through an 
interaction with stressful 
events. According to 
hopelessness theory59, 
individuals with negative 
attribution styles perceive 
stressful events as due to 
persistent and immutable causes, as having further stressful consequences, and as being precipi[INVESTIGATOR_105064]. Therefore, when an individual with a negative cognitive style experiences a 
painful or challenging event, he s/he tends to hold him/herself responsible for the cause, assumes that 
this negative experience will recur repeatedly, and that this same experience will generalize to multiple 
situations60. Numerous studies provide evidence that negative cognitive style predicts depression in adolescents61-63. Personality types prone to self-criticism or in need of others’ approval are also 
predisposed to depression64. Additionally, self-critics have less of an ability to self-soothe in times of 
stress65, and this inability has been linked to depression66-69.  In addition, shame  has been linked to 
depressive symptoms in various adolescent populations58,70-75.  At times emerging from repeated self-
criticism, shame is defined as a global negative evaluation of the self, resulting in a sense of a shrinking, 

Master Protocol 
S.M.A.R.T. Project Page 15 of 147  version 1.1  
01 March 2021 
 small, powerless and worthless self75, and a concern that the self will be exposed as defective76. Shame 
is experienced as stable and unremitting over time, and shame-prone individuals often exhibit a 
negative cognitive style70,77-79. 
Rumination , a method of copi[INVESTIGATOR_105065], has been described as having two components: 
reflection and brooding. Brooding is characterized by [CONTACT_105105]80. In addition, rumination, in general, has consistently predicted 
increases in depressive symptoms in children and adolescents81-84. Finally, resilience,  or the ability to 
bounce back from stress85, has been negatively associated with depression in numerous studies85,[ADDRESS_116700] included cognitive 
behavioral therapy (CBT)88-98, psycho-educational interventions99-101, problem solving102,103, and 
behavioral skills training interventions (e.g., interpersonal relationship building and social skills)94,99,104-
106. A meta-analysis of depression-prevention programs for youth reported that only 41% of the 
programs included in the study had significant reductions in depressive symptoms post intervention and 
the effect sizes were small ( r = .[ADDRESS_116701]; r = .11 pre to follow-up)9. Additionally, many of the trials 
had either waitlist or assessment-only control conditions, which are likely to overestimate effect sizes 
(e.g., one study that compared a CBT treatment group with four active control groups and a waitlist 
control found that all active controls and CBT outperformed the waitlist control107). Furthermore, only [ADDRESS_116702] effective programs utilized professional interventionists (rather than 
classroom teachers), assigned homework, and were relatively short in length9. Also, the developmental 
appropriateness of CBT for adolescents has been questioned, as these youth may not be able to fully 
grasp the concepts foundational to CBT. Third-wave therapi[INVESTIGATOR_105066], although popular in clinical practice, have few well-controlled 
clinical trials108. Based on the mixed success of well-studied behavioral interventions, there is a need to 
investigate new approaches to depression prevention that are tailored to the developmental needs of 
the adolescent population.  
Mindfulness-based Self-Compassion: An Antidote for Depression?   
One promising approach is mindfulness-based self-compassion training. Mindfulness has been defined 
as paying attention to the present moment with nonjudgmental awareness109. It includes recognition of 
thoughts or emotions that are in one’s momentary experience and subsequently “letting go” of those 
emotions or thoughts, acknowledging that they are transitory110. Mindfulness-training interventions, 
most notably Mindfulness-Based Stress Reduction (MBSR)25,teaches skills that increase one’s ability to 
be more mindful in everyday life. In adults, these studies are conclusively shown to lower depression111-
[ADDRESS_116703] size was reported for mindfulness interventions on 
improving mood in individuals with diagnosed depression (Hedges g = .95)117. 
Although mindfulness research with adolescents is nascent, studies show that greater mindfulness is 
indicative of improved psychological wellbeing. A recent meta-analysis on mindfulness interventions 
with youth reported a moderate effect size (Cohen’s d=.37) for psychological symptoms, and a large 
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116704] size for studies that used a clinical sample (Cohen’s d=.50)118.  Specifically, post-intervention, 
depression was shown to decrease in a clinical sample17 and rumination decreased in 4th and 5th grade 
public school students119. Mindfulness was correlated negatively with perceived stress in one study15, 
and mindfulness training resulted in decreased stress in clinic-referred adolescents in another study17. 
Other studies found significantly improved overall wellbeing120 and decreased depressive symptoms121.  
Both mindfulness and self-compassion independently contribute to improvements in psychological 
health122. Self-compassion, as defined by [CONTACT_105106]26, is described as being open and present to one’s own 
suffering, to actively heal oneself with kindness, and to understand that one’s suffering is inherent in the 
human experience and as such is shared among others. Neff defines three components of self-
compassion: mindfulness, or maintaining perspective amidst challenging circumstances; common 
humanity, or recognizing that one is integrally connected to a network of imperfect human beings, and 
self-kindness, or treating oneself with tenderness when one is suffering26.  Greater self-compassion is 
associated with lower depression, anxiety, and stress in both adults13,123-[ADDRESS_116705] lower depression symptomology over a 5-month 
interval13, supporting the theory that "self-compassion represents a potentially important protective 
factor for emotional problems such as depression." (p. 33).  
Neff and Germer developed the Mindful Self-compassion program (MSC) for both clinical and non-
clinical applications14. MSC meets weekly for 8 weeks, and involves didactic instruction as well as 
practice of self-compassion exercises. A clinical trial of this program has demonstrated significant 
decreases in anxiety, depression (large effect size compared to wait-list control), and stress that were 
maintained at both 6 and 12 month follow-up14.  A similar program, developed for patients with mood 
disorders, resulted in marked decreases in depression134. At UNC, in collaboration with our colleagues at 
University of [LOCATION_004]-San Diego (UCSD), we have developed a mindfulness-based self-compassion 
program for adolescents and tested it in a non-clinical, teen population.   
Development of a Mindfulness-based Self-Compassion Program for Adolescents with 
Subsyndromal Depression: “Making Friends with Yourself”  
This R-[ADDRESS_116706] the feasibility of a mindfulness-based self-compassion training 
program for adolescents who are experiencing subsyndromal depression, comparing it with a “healthy 
lifestyles” group program, which is based on a program developed by [CONTACT_105107] a control condition 
for mindfulness studies with adolescents, and which will be adapted in length and content as a 
comparison attention-control for the treatment intervention. Our mindfulness-based self-compassion 
program, “Making Friends with Yourself”, adapts the MSC format and contains elements of it. It is 
guided by [CONTACT_105108]-compassion26: self-kindness, common humanity, and mindfulness. It differs from the adult program in that classes will be shorter, developmentally 
appropriate (e.g., more activity-based such as games and role-plays), includes a component about the 
adolescent brain, a mindful movement segment halfway through each class, and shorter meditations. 
Treating oneself kindly and experiencing oneself as part of a common humanity is posited to shift 
negative cognitive style so that inferences related to self are less negative. Developi[INVESTIGATOR_105067]. Keepi[INVESTIGATOR_105068] 
(mindfulness) is posited to also shift negative cognitive style, as well as decrease brooding (negative 
rumination). Further, both shame and rumination are known to correlate with negative cognitive 
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116707] pi[INVESTIGATOR_105069] (see preliminary studies ). It has been tested as a 6-session 
course with community adolescents, and results from the Borkovec and Nau credibility scale138 indicated 
no difference in adolescents’ perceived credibility between the control and intervention programs. We 
are now proposing to expand it to eight sessions and test it with a different population, specifically 
adolescents with subsyndromal depression. For this project, with our clinician coinvestigators, we will 
expand and refine this program, in order to develop a suitable control condition for a future RCT. The 
program is similar to lifestyle group programs offered to at-risk adolescents by [CONTACT_15957]-I April Harris-Britt, 
PhD.   
Preliminary Studies                                                                               
In the past two years, our group has investigated outcomes associated with mindfulness training for 
adolescents and has developed and pi[INVESTIGATOR_31219] a prototype of a mindfulness-based self-compassion 
program for adolescents. In the first study, one aim was to determine how a self-report measure of self-
compassion correlated with self-reported emotional wellbeing and impacted response to a lab social 
stressor.  Male and female adolescents (n=28) ages 13 to 18 were randomized to a six-week mindfulness 
program adapted for teens entitled “Learning to Breathe” or an attention-control intervention, “Healthy 
Lifestyles”, which involved education and discussion about ways in which they might make more healthy 
choices in relation to behavior (e.g. nutrition, sleep, exercise). Participants completed a teen-adapted 
Trier Social Stress Test (TSST) in a lab setting, with physiological stress assessed via salivary cortisol, 
heart rate, blood pressure, and heart rate variability at baseline, during the TSST, and during recovery 
along with measures of perceived stress, life satisfaction, positive and negative affect. We analyzed the 
TSST for induction of a significant stress response, and assessed meaningful differences (Hedges’ g > .20) 
between the groups. Those in the high self-compassion group (equal to or above the median) self-
reported greater emotional wellbeing across all measures than those in the low self-compassion group 
(below the median) (Table 1).  Table 1. Results for mean differences of low and high self -compassion on indicators of wellbeing  
 Mean (SD)   
 LSC 
(n = 12) HSC 
(n = 16) Hedge’s g (95% CI)  
Anxiety  36.50 (8.25)  31.75 (6.38)  0.64 [ -0.11, 1.38]  
Perceived Stress  32.08 (5.66)  27.50 (7.76)  0.64 [0.11, 1.39]  
Negative Affect  24.50 (7.72)  20.62 (6.67)  0.53 [0.21, 1.27]  
Positive Affect  29.67 (6.02)  31.19 (8.19)  -0.20 [-0.91, 0.53]  
Life Satisfaction  2.33 (0.38)  2.72 (0.65)  -1.18 [ -0.93, 0.53]  
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116708].   
In our second study , we developed and 
pi[INVESTIGATOR_2268]-tested a prototype of Making Friends 
with Yourself, adapted from the Neff & 
Germer Mindful Self-Compassion program 
for adults. We used a mixed-methods 
wait-list control in which participants 
completed online measures of 
mindfulness, self-compassion, and 
dimensions of emotional wellbeing 
measures before and after the course. 
Most notably, we found a 25% decrease in 
depressive symptoms in the intervention 
group, in addition to statistically significant 
changes in all measures except life 
satisfaction, social connectedness, and positive affect. In the waitlist control condition, no significant 
pre-post differences were present in any of the measures (Figure 3). Together, changes in mindfulness 
and self-compassion  significantly predicted changes in depression, perceived stress, anxiety, and life 
satisfaction post-intervention (p<.05).    
Interestingly, at baseline, the link between stress and depression was stronger in those with low self-
compassion compared to those with high self-compassion (β = -.31, p = .02), indicating that these low 
self-compassionate adolescents may more easily become depressed when faced with stress. This 
finding, linked with findings from the first study, indicate that adolescents with low self-compassion are 
likely to be more easily stressed and therefore more easily depressed.    
Impact 
Depression among 
adolescents is a prevalent 
and growing public health 
problem, the consequences 
of which have significant, 
long-term negative impacts 
for the individual, their 
families, and society. This 
innovative project, in a 
high-priority NCCIH area, 
will test the feasibility of a 
promising, novel, 
depression-prevention 
program adapted from a Note. CI = Confidence interval; LSC = Low Self -Compassion; HSC = High Self -Compassion * p < 0.[ADDRESS_116709] Page 19 of 147  version 1.1  
01 March 2021 
 successful adult Mindful Self-Compassion program.  “Making Friends with Yourself” (MFY) will be refined 
and manualized, as well as feasibility-tested in an exploratory clinical trial, in adolescents who 
experience subsyndromal depression. It will also refine and test the comparative feasibility of an 
attention-control condition, pi[INVESTIGATOR_105070] a mindfulness intervention for adolescents, to be 
adapted as a control intervention for this study. The measures selected for feasibility testing are 
theoretically meaningful and likely able to elucidate mechanisms by [CONTACT_105109]. This information can be used to plan a future randomized trial. Reinforcing the 
potential impact is the collective extensive experience of the investigative team, including their 
experience with this population and in designing, implementing, and evaluating similar studies, as well 
as the supportive research environment of the University of North Carolina at Chapel Hill.  If this 
manualized program proves acceptable, feasible and efficacious, there is great potential for its use in 
schools and other adolescent settings, thus amplifying its potential impact on reducing depression by 
[CONTACT_105110].  
3. STUDY DESIGN 
In this study, we will refine and feasibility-test our mindful self-compassion program and an attention 
control program with a focus on adolescents who are experiencing subsyndromal depression. 
Subsyndromal to mild depression is defined as a score of at least 6 and 10 on the Quick Inventory of 
Depressive Symptoms (QIDS). The intervention program, called “Making Friends with Yourself” (MFY), 
implements mindfulness and self-compassion training. The control condition is a healthy lifestyle 
program for high-school aged adolescents. The control condition was developed by [CONTACT_105111][INVESTIGATOR_105071]. The 8-week programs will be pi[INVESTIGATOR_60528] a total of [ADDRESS_116710] through the program, after the 8-week program (intervention phase), and 
3 and 36 weeks after program completion (continuation phase). Feedback from program participants 
will inform modifications and refinement of both programs.  
Our primary goal is to examine the feasibility of implementing the program. After feasibility, the primary 
outcome to be explored will be the occurrence of incident major depressive disorder (MDD) with a 
secondary outcome to be explored being the trajectory of depressive symptoms over time (measured at 
baseline, program end and at [ADDRESS_116711] program) using the Short Mood and Feelings 
Questionnaire (SMFQ) administered to both the adolescent and a parent. Studies indicate high 
predictive validity in adolescent self-report of depression139,140. The study psychologist will contact [CONTACT_105112], captured by [CONTACT_105113]-
points during the study, for referral to appropriate mental health care.  
Randomization will be stratified by [CONTACT_547]. As soon as [ADDRESS_116712] Page 20 of 147  version 1.1  
01 March 2021 
 number of subjects allocated to the two arms over time are equal and to conceal the allocation. This will 
continue through 4 cohorts of adolescents (n=80). During participation, adolescents will keep a daily 
online diary, accessible from a cell phone, to document homework practice. Their engagement in the 
program will be captured by [CONTACT_105114][INVESTIGATOR_105072]. After each program’s completion, 
adolescents will participate in a focus group to 
give feedback about program contents. The 
adolescents will be invited to participate in [ADDRESS_116713]-participation 
questionnaires. This will be analyzed using 
qualitative methods to inform revision of specific 
program components and the revision of detailed 
program manuals for future programs. 
3.1: Recruitment, screening and consent  
Recruitment 
We will recruit adolescents who are experiencing 
subsyndromal depression in three ways:   
1) Discussions with local guidance counselors and school personnel;  
2) University-wide emails to the University community; and  
3) Flyers posted in local high schools/community boards (a successful strategy in our preliminary 
studies).  
Members of our study team have established relationships with personnel in several of the local school 
systems. This has been successful in meeting targeted recruitment numbers in previous research 
studies.  
Screening 
If an adolescent or parent is interested in the study, they can begin the screening process through the 
following ways: 
1) Phone: interested participants can initially contact [CONTACT_105115]; 
2) Email : interested participants can initially contact [CONTACT_105116]’s email 
([EMAIL_2060] ); 

Master Protocol 
S.M.A.R.T. Project Page 21 of 147  version 1.1  
01 March 2021 
 3) Study Website : parents of interested participants can initially contact [CONTACT_105117] ( http://smartstudy.web.unc.edu/parent-survey/ );  
The study team will explain the study to interested parents and, with permission, arrange for the 
adolescent to complete the online screening, which includes the Quick Inventory for Depressive 
Symptomology (QIDS). Adolescents who meet pre-screen eligibility criteria (see Section 4. Selection and 
Enrollment of Participants ) and their parent will then meet with a study team member to review study 
procedures in detail and provide informed consent and assent (see Section 4.3: Study Enrollment 
Procedures  and Section 6.2: Description of Evaluations ). Potentially eligible adolescents and a parent will 
then meet with the Study Psychologist for a clinical mental health assessment. 
4. Selection and Enrollment of Participants 
4.1: Inclusion Criteria 
Participants must meet all of the inclusion criteria to participate in this study. Inclusion criteria for the 
study includes: 
 Adolescents between ages 14-17. Adolescents may turn 18 after enrollment.  
 Adolescents who are in high school.  
 Adolescents with access to a smartphone or internet-enabled device.  
 Adolescents and parent willing for their adolescent to be randomized to one of the two groups.  
 Adolescent able to attend group sessions (8 weekly, 1.75 hour sessions; 6 monthly, 1.5 hour 
sessions) and complete study assessments.  
 Adolescents experiencing subsyndromal depression assessed by:  
o Completion of screening questions by [CONTACT_7078] (see Parent Screening Survey  and 
Telephone Consent);  
o Completion of QIDS by [CONTACT_105118] (see ;  
o Completion of clinical mental health assessment based on Diagnostic Interview Schedule 
for Children for Children (DISC-IV) by a study provider. The clinical mental health Figure 5. Flow of Interested Participants through the Screening Process
 
 Interested Person
Participants recruited 
through  schools or self-
referralsPermission to 
Contact
[CONTACT_105119], if 
the participant contacts the 
study directly.Telephone 
Screen
A study team member 
provides info about the 
study and conducts a brief 
eligibility review with 
parent and teen.QIDS 
Depression 
Screen
A study team member 
sends QIDS  survey to 
participant. After 
completed, it is 
reviewed and baseline 
appointment is set up if 
criteria met.
Master Protocol 
S.M.A.R.T. Project Page 22 of 147  version 1.1  
01 March 2021 
 assessment will screen for serious psychiatric illness, including major depression (MDD), 
suicidality, and other exclusion criteria.  
Preliminary identification of subsyndromal depression will occur through screening questions completed by 
[CONTACT_7071] (see Telephone Consent for details) and completion of QIDS by [CONTACT_105118].  
Adolescent and parent willing to receive a clinical mental health assessment, administered by a study 
provider, based on the Diagnostic Interview Schedule for Children-IV (DISC-IV) to screen for serious 
psychiatric illness, including major depression (MDD) and suicidality.  
4.2: Exclusion Criteria 
All candidates meeting any of the exclusion criteria at baseline will be excluded from study 
participation. Exclusion Criteria include: 
 Adolescent and parent unable to speak, write, and read in English. 
 Adolescents who have received prior mindfulness training (such as a mindfulness course).  
 Adolescent unable or unwilling to attend or  participate in group sessions and/or self-report 
assessments. 
 Adolescents with the presence of suicidality or MDD as determined by [CONTACT_461]. 
Adolescents who have experienced MDD in the past will not automatically be excluded from the 
study. 
 Adolescents with active substance abuse, defined as active treatment for substance abuse, legal 
consequences/school suspensions associated with substance use, or ongoing family conflict 
associated with substance use. 
 Adolescents with a history of bipolar disorder, schizophrenia, severe autism/intellectual 
disability, or psychiatric hospi[INVESTIGATOR_75719] 36 weeks. Milder forms of mental health 
and/or developmental disorders will not automatically constitute exclusion. The Study 
Psychologist will recommend exclusion only if the disorder would lead to disruption of the group 
process. 
 Adolescents who currently or previously participated in a research intervention to address 
depression or psychiatric conditions. Adolescents are allowed to see their mental health 
provider while participating in the study. 
4.3: Study Enrollment Procedures  
We will recruit teens, ages 14-17, who are in high school and have subsyndromal depression, in several 
ways including:  
 Emails with study information sent to the University community; 
 Local guidance counselors made aware of the study;  
 Flyers posted in the community and at local schools; 
 In-person recruitment at local teen community organizations, churches, and school events 
(such as parent-teacher associations or parent-teacher organizations). 
Master Protocol 
S.M.A.R.T. Project Page 23 of 147  version 1.1  
01 March 2021 
 4.3.1: Phone Screening and Psychological Exam  
The study staff will contact [CONTACT_105120], with consent and assent, conduct an initial 
telephone screen with the adolescent. If still interested, materials will be sent to the parent to share 
with the adolescent, describing the study as two programs to help teens to reduce stress and feel more 
positive about themselves. Candidates will be given the QIDS assessment and if their score is at least 6, 
the teen and a parent will be eligible for a visit with the Study Psychologist for a clinical mental health 
assessment.  
4.3.2: Consenting  
If a teen is eligible to participate based on the QIDS, the parent and teen will meet with a study team 
member to review study procedures in detail and provide written informed consent and assent.  Any 
questions asked by [CONTACT_105121]. They may decline, sign, or take 
the consent home with them to be signed later. The adolescent will considered to be a subject after 
both the Informed consent is signed by [CONTACT_105122].  
At that time, if consented, the teen and parent will meet with the Study Psychologist for a psychological 
exam, including a face-to-face administration of the Diagnostic Interview Schedule for Children (DISC-
IV). The clinical mental health assessment will determine continued eligibility. 
4.3.3: Documentation 
The study team will maintain a screening log on REDCap (a secure, web-based research database) 
throughout the study. This will include names, dates of contact, and outcomes of the recruiting effort 
for each candidate. At all stages of the recruitment process, the study team will store any written 
documentation securely in locked study cabinets.  
4.3.4: Randomization 
Although the study is not designed as an RCT, we do plan to test our randomization system. In all but the 
first two cohorts, as soon as 14-20 eligible adolescents qualify for enrollment, they will be allocated to 
one of the educational groups, using a specially-designed computer program (in REDCap). This program 
requires the operator to check off inclusion/exclusion criterion for each subject and confirm that 
subjects have been consented. The program utilizes a random-numbers generator with a permuted 
block design (blocks of 2 to 4) to ensure that the numbers of subjects allocated to the two arms over 
time are equal and to conceal the allocation. Randomization is stratified by [CONTACT_547]. 
5. STUDY INTERVENTIONS  
5.1: Interventions, Administration, and Duration  
5.1.1: Prevention Programs 
Each program will be [ADDRESS_116714] and parent will complete baseline measures through an electronic 
interface (REDap survey). A trained instructor, assisted by a mental health provider (including mentored 
psychologist/social work interns or school counselors) who work with adolescents will lead each 
program. Mental health providers or their supervised students will identify any behaviors that may 
indicate deteriorating mental health status and confer with the Study Psychologist. Instructors of the 
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116715] 
learned. 
Making Friends with Yourself Curriculum 
The MFY program will be led by [CONTACT_105123]-compassion instructor trained in teaching 
the teen program and assisted by a mental health provider who works with teens. The curriculum will be 
adapted from the adult program in that it will be developmentally appropriate for adolescents. The 
team has developed a Chatbot for the study to reinforce concepts that are learned in class. For example, 
participants can choose emotion words to express how they are feeling in a given moment; the chatbot 
will then provide them with a short practice to help them be mindful and self-compassionate.  
The MFY curriculum will contain the following:  
 Session 1 : Discovering Mindful Self-Compassion: Definitions of mindfulness and self-
compassion will be provided. Guided meditation is presented. Through a hands-on exercise, 
students become familiar with the concept that we treat ourselves more harshly than we 
treat our friends in time of difficulty. 
 Session 2 : Paying Attention on Purpose: Mindfulness concept is presented. Sound 
meditation, eating meditation, and a body scan are introduced. 
 Session 3 : Lovingkindness: Concept of lovingkindness is introduced, along with 
lovingkindness practices. Included is how to tailor lovingkindness practices to meet one’s 
own personal needs. 
 Session 4 :  Self-Compassion: Definition of self-compassion is articulated through guided 
meditations and exercises. Music meditation is introduced. 
 Session 5 :  Self-Compassion vs. Self-Esteem: The similarity and differences of these two 
ways of relating to oneself are presented.  
 Session 6 :  Living Deeply: The compassionate voice is contrasted with the voice of the Inner 
Critic. An art and writing activity is incorporated into the lesson. 
 Session 7 :  Managing Difficult Emotions: Adolescents are taught specific tools to deal with 
particularly emotionally challenging situations, i.e., those that potentially could increase 
anxiety or depression.  
 Session 8 :  Embracing Your Life: Focus is on how to integrate gratitude and self-appreciation 
practices into daily life. 
 
Continuation sessions, 90-minutes in length, will be held monthly and revisit aspects of the class 
content.  
Master Protocol 
S.M.A.R.T. Project Page 25 of 147  version 1.1  
01 March 2021 
 Healthy Lifestyles Group (HLG) 
An experienced facilitator will lead the HLG curriculum and will be assisted by a mental health provider. 
The program focuses on the development of healthy lifestyles for adolescents. Each session involves the 
introduction of the weekly topic by [CONTACT_105124]-on activities and discussion. A 
mobile friendly website will be explored to help reinforce concepts learned in this class and participants 
will complete homework related to the class content. The HLG curriculum will contain the following 
topi[INVESTIGATOR_1102], adjusted with feedback from the participants:  
 Session 1 : Sleep hygiene: The science behind sleep and its effects on the brain   
 Session 2 : Nutrition: Eating well for a healthy body and healthy mind 
 Session 3 : Exercise: Getting moving to feel better 
 Session 4 : Academic Stress: Overcoming School Stress 
 Session 5 : Social media—Instagram, Twitter and beyond: How to manage this in your life 
without it overtaking your life  
 Session 6 : Creativity: Shapi[INVESTIGATOR_105073] 
 Session 7 : Diversity: Exploring your Identity 
 Session 8 : Community service: Engaged Citizenship 
Continuation sessions, 90-minutes in length, will be held monthly and revisit aspects of the class 
content. 
5.1.2: Measurement Time Points 
Adolescents will be evaluated at baseline (Visit 2), halfway through the intervention (Visit 6), after the 
intervention (Visit 10), in the middle of the continuation phase (Visit 13), and after the continuation 
phase (Visit 16). Parents complete the SMFQ-P evaluating their perception of their child’s depressive 
symptoms at baseline (Visit 2), post-program (Visit 10), and the continuation visits (Visit 13 and Visit 16). 
The PROMIS Pediatric Depression Scale, originally designed as a safety measure, is employed as the 
time-to-event measure. 
5.1.3: Measures 
Several measures will be used for the study. Table [ADDRESS_116716](s) it assesses, and 
the timepoint it is administered in the study. 
Measures Used For Pre-Screening 
Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR)141: Adolescents will complete 
the QIDS self-report as a screening  measure for depression. The sixteen-item QIDS is highly correlated 
with the full Inventory of Depressive Symptomatology and is limited to the nine DSM-IV domains: 1) sad 
mood; 2) concentration; 3) self-criticism; 4) suicidal ideation; 5) interest; 6) energy/fatigue; 7) sleep 
disturbance; 8) appetite change; 9) psychomotor changes. The QIDS is a reliable (α=.86) measure141 that 
compares favorably with other depression measures142 and has been investigated in adolescents143. A 
score of 6-10 is consistent with subsyndromal to mild depression. The QIDS will be completed following 
the telephone screen to determine eligibility to come in for an enrollment visit. 
Diagnostic Interview Schedule for Children- Version IV (DISC-IV)144: The DISC-IV assesses psychiatric 
diagnoses of children and adolescents by [CONTACT_105125] – Fourth Edition (DSM-IV) and the WHO International 
Classification of Diseases, Version 10 (IDC-10). The DISC is a highly structured interview for children and 
Master Protocol 
S.M.A.R.T. Project Page 26 of 147  version 1.1  
01 March 2021 
 adolescents aged 6 to 18, or their parents. The DISC was designed to be administered by [CONTACT_105126] a training manual. Questions are worded so that they can be answered “yes”, “no”, and 
“somewhat” or “sometimes”. The DISC-IV is used as a guide by [CONTACT_105127] (baseline) visit.  
PROMIS Pediatric Depression Scale.  The Patient Reported Outcomes Mesurement Information System 
was funded and promulgated by [CONTACT_105128] a way to harmonize across 
measures.  They included measures specifically for pediatric populations, including adolescents.  One 
such measure is the pediatric depression short form.   The short form was chosen as a safety measure 
for this study because of its simplicity, its brevity (8 questions), and its ability to be administered and 
scored electronically using REDCap.  Because it was administered weekly, it also serves as an excellent 
measure to use for a time-to-event analysis. 
Short Mood and Feelings Questionnaire (SMFQ)145: The SMFQ is a depression scale created for children 
and adolescents. There is a 13-item youth version (SMFQ-C)  and 13-item parent version (SMFQ-P ). 
Items are symptoms of depression experienced over the past 2 weeks which the child or parent would 
endorse as “not true”, “sometimes true” or “true”. Internal reliability has been reported as α=.85 
(SMFQ-C) and α=.87 (SMFQ-P)146,147.  
Brief Resiliency Scale (BRS)85: This scale defines resiliency as the ability to “bounce back” and recover 
from stress; the items reflect a sense of personal agency. Six items are rated on a scale from 1 ( strongly 
disagree ) to 5 ( strongly agree ). Convergent and discriminant validity have been established, and 
Cronbach’s alpha is between .[ADDRESS_116717] reliability over one month has been reported as .69 
and >22 weeks as .62.  
Adolescent Cognitive Style Questionnaire (ACSQ)148: The ACSQ assesses the extent to which 
adolescents utilize a negative cognitive style. Twelve hypothetical negative event scenarios are 
presented that are relevant to teens, and the participant is asked to write down one potential cause for 
the event. Participants then rate the degree to which the cause is 1) internal, 2) stable, and 3) global, the 
likelihood for future negative consequences to occur as a result, and the degree to which the result 
implies that the self is flawed. Construct validity was supported through correlations with other 
attributional style measures and depressive symptoms, and the scale demonstrated internal consistency 
(α =.95) and test-retest reliability (.73 over 2 weeks). Reliability and validity remain consistent with using 
as few as four scenarios. This study uses six of the twelve scenarios (items 1, 2, 3, 6, 8, and 12) that are 
relevant to the study population. Items not as relevant (e.g. attending college, having a boss) or that 
were redundant (e.g. questions dealing with boyfriends/girlfriends or grades) were not included for this 
study to reduce participant burden with answering questions.  
Ruminative Response Style scale – brooding factor (RRS-B)80,149: Five items from the [ADDRESS_116718] strongly with depression. On a scale from 1 (never/almost never) to 4 (always/almost 
always), participants are asked to indicate how often they would initiate a specific response when they 
were upset. The 5-item scale has been used previously in a study with adolescents and correlate highly 
with the full rumination scale ( r=.93); internal consistency for this shortened scale was good (α=.82) and 
test-retest reliability was good150. 
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116719] for  Adolescents (TOSCA-A)151: This scale was developed to assess 
proneness to shame, proneness to guilt, externalization of blame, detachment-unconcern, and pride in 
self and pride in behavior. The scale is comprised of 15 scenarios (10 negative, 5 positive) that might 
occur in the everyday life of an adolescent. Participants are asked to indicate on a 5-point scale their 
likelihood of reacting with each response. TOSCA is correlated with measures of anger, empathy, and 
psychological symptoms, and internal consistency was good (shame, α =.77; guilt, α =.81) 
Self-Compassion Scale (SCS)124 (26 items): The self-compassion subscales are self-kindness, common 
humanity, and mindfulness. Participants indicated their responses to each item using a 5-point scale 
ranging from 1 ( almost never)  to 5 ( almost always) . Construct validity was established through expected 
correlations with the self-criticism subscale of the Depression Experience Questionnaire, the Social 
Connectedness scale, and the attention, clarity, and repair subscales of the Trait-Meta Mood Scale. 
Internal consistency for this scale was found to be excellent (α = .93).   
Child and Adolescent Mindfulness Measure (CAMM)16: CAMM assesses mindful awareness and acceptance. Participants indicate their responses to 10 items using a 5-point scale ranging from 0 ( never  
true)  to 4 ( always true).  Construct validity was established through positive correlations with measures 
of quality of life, academic competence, and social skills and negative correlations with measures of 
somatic complaints, and internalizing and externalizing behavior problems; adequate internal 
consistency also was found (α = .80). 
Expectations of Benefit / Credibility (CRED)138,152: This instrument, administered at the end of the first 
class,  provides an assessment of expectation of benefit and credibility of each intervention using an 
adaptation of a validated scale previously developed for psychological studies for purposes of comparing 
two treatment arms. Participants respond to 6 items on a 9-point scale ranging from 1 ( not at all ) to 9 
(very much ). Psychometric testing supported high internal consistency within each factor (expectation, α 
= .90; credibility, α = .86) and good test-retest reliability (.83). 
Feelings About the Class: This is a process questionnaire developed for Gregory Clarke’s “Copi[INVESTIGATOR_105074]” program to assess subjects’ feelings about the instructors and other class participants as well as 
satisfaction with the program.  It will be administered at the end of the intervention phase (at the last 
class) for both programs with permission of the author. 
Home Practice Completion (Daily Diary) : Adolescents in the intervention program will be expected to 
practice concepts taught in the class. Each day, they will receive a text message (or email) from the 
study team.  Embedded in the text or email will be a link to the diary website. The daily diary will consist 
of no more than 5 short questions about skills they practiced, number of minutes they practiced, and 
any barriers to practice. 
Patient-Reported Outcomes Measurement Information System Pediatric Short Form (PROMIS 
Pediatric Short Form): The PROMIS Pediatric Short Form is a short 12-item survey designed to screen for 
depression. The PROMIS Pediatric Short Form will be used as a safety measure once participants are in 
the 8-week course to assess any changes in depressive symptoms. See 7. Safety Assessments  for more 
details about the PROMIS Pediatric Short Form being used as a safety measure for the study. A T score 
of [ADDRESS_116720] Page 28 of 147  version 1.1  
01 March 2021 
 Demographics : The study is limited to adolescents experiencing subsyndromal depression. The 
demographic survey, administered at baseline, will collect data about each teen’s age, gender, 
race/ethnicity, years of education, and parental educational attainment. 
Qualitative measures: We will collect two types of formal qualitative data: 1) Evaluation (focus) groups 
following each 8-week set of classes at the end of the last class; 2) Transcriptions of audio-recorded 
classes. The focus groups will address the following topi[INVESTIGATOR_105075]’ experience with the 
programs, including:  
1) Most memorable aspects of program (e.g. most favorite and least favorite aspects); 
2) Whether they would recommend it to a friend;  
3) Usefulness, challenges and recommended changes including in-class and out-of-class 
assignments;  
4) Usefulness of the program for management of stress, mood, and well-being in daily life;  
5) Tools that might help them maintain practices; and  
6) Unfulfilled expectations of the program.  
 Each focus group will be audio-recorded and transcribed. 
Table 2. Study measures    
MEASURE CONSTRUCT TIMING 
Inclusion/Exclusion Criteria 
QIDS-SR Depression screening Pre-screening 
Diagnostic Interview Schedule for Children (DISC-
IV) Screening for serious 
psychopathology Screening visit 
Primary Outcomes 
PROMIS Pediatric Depression Short Form v1.1 Incident major depression Weekly from the beginning of the 
intervention 
Secondary Outcomes 
Short Mood and Feelings Questionnaire (SMFQ-C) Depression scores change Visit 2, Visit 6, Visit 10, Visit 13, Visit 16 
Brief Resiliency Scale (BRS) Resiliency Visit 2, Visit 6, Visit 10, Visit 13, Visit 16 
Exploratory Mediating Measures 
Adolescent Cognitive Style Questionnaire (ASCSQ) Cognitive Style Visit 2, Visit 6, Visit 10, Visit 13, Visit 16 
Rumination Response Style-brooding factor (RRS-B) Brooding Visit 2, Visit 6, Visit 10, Visit 13, Visit [ADDRESS_116721]-adolescence (TOSCA-A) Shame Visit 2, Visit 6, Visit 10, Visit 13, Visit 16 
Process Measures 
Home-practice (HW) Homework completion Daily during program, then weekly 
Pediatric Depressive Symptoms Short Form (PDS) Safety assessment for depression Weekly during program 
Self-Compassion Scale (SCS) Self-compassion Visit 2, Visit 6, Visit 10, Visit 13, Visit 16 
Child and Adolescent Mindfulness Measure 
(CAMM) Mindfulness Visit 2, Visit 6, Visit 10, Visit 13, Visit 16 
Credibility Scale (CRED) Expectation of benefit Following first class 
Feelings about the class Post-participation evaluation Visit [ADDRESS_116722] through, 
and after the program as well as at 22 weeks and 36 weeks after the program.  
Feedback from program participants and their parents will inform modifications and refinement of both 
programs. Once this has been completed and program manuals updated, an additional 2 cohorts will be 
recruited. 
5.2: Handling of Study Interventions  
A Manual of Operations will be actively maintained to document subject participation in all aspects of 
the project including, for examples, attendance at weekly session visits, completion of homework and 
online assessments, and follow up questionnaires. 
5.2.1: Masking  
The nature of the interventions tested in this study does not allow for masking of subjects, instructors, 
or other personnel involved in program delivery. To preserve unbiased outcome assessments, study 
personnel involved in clinical assessments or data analysis will be masked with respect to group 
assignment. To minimize differences in subject expectancy, the programs will be described to 
participants as two programs, both of which have been previously found to be beneficial to teens. 
Participants will not know the name [CONTACT_105157]: Making Friends with Yourself or Healthy Lifestyle 
Group. The intent is to prevent the participant from knowing which program the investigators believe is 
most likely to prevent depression. To verify that adolescents assigned to either group have the same 
expectation of benefit, participants will be asked to complete a Credibility Scale138 at the end of Session 
1. 
5.3: Concomitant Interventions  
5.3.1: Allowable Interventions  
Participating adolescents may continue to receive medical care from their primary care provider.   
5.3.2: Required Interventions 
Participants are expected to attend baseline visits, 8 weekly classes, and 6 continuation classes. In 
addition, they are encouraged to complete homework diaries (daily during the intervention, then weekly 
during the continuation sessions), weekly depression screens, and questionnaires at Visits 2, 6, 10, 13, 
and 16. Parent Measures 
Demographics   Visit 2 
Short Mood and Feelings Questionnaire (SMFQ-P) Parent perception of adolescent’s 
depression Visit 2, Visit 6, Visit 10, Visit 13, Visit [ADDRESS_116723] Page 30 of 147  version 1.1  
01 March 2021 
 5.3.3: Prohibited Interventions  
Participants will be excluded from enrolling in the program if they have participated in a mindfulness-
training program. They will be asked not to participate in any other mental health intervention study 
during their participation in this study, which includes a study on medications or other group 
interventions. Participants who do not develop major depression may follow the advice of their 
physicians and primary care providers and may take any prescribed medication. Participants who 
develop major depression during the study will be referred to a mental health provider. 
5.4: Adherence Assessment  
We will define study adherence as 80% compliance with the home practice and self-report assessments   
and attendance at 6 out of 8 weekly sessions  and 4 out of 6 continuation sessions. 
6. STUDY PROCEDURES  
6.1: Schedule of Evaluations  
Participants will follow the schedule in Table 3 to complete consenting and assessments: 
Table 3. Schedule of Evaluations  
Assessment Visit 1 
Screen 
and 
Baseline  Before 
Visit 2  
(online)  Visit 2  
(W0)  Daily 
(W0-8)  Visits 
3-5 
(W1-3) Visit 6  
(W4) Visits 
7-9 
(W5-7) Visit 
10 
(W8)  Visit 
11-12 
(W13, 
17) Visit 
13 
(W22)  Visit 
14-15  
(W27, 
32) Visit 
16 
FINAL 
(W36)  
Informed Consent X            
Demographics  X            
Enrollment  X            
Psychological X            
Inclusion/Exclusio X            
Questionnaires   X    X  X  X  X 
Randomization   X           
Credibility   X          
Daily practice diary     X         
Weekly practice         X X X X 
Weekly depression   X  X X X X X X X X 
Focus Group         X    X 
Parent measures   X      X  X  X 
6.2: Description of Evaluations 
6.2.[ADDRESS_116724] of the following: 
 Potentially eligible participants will be identified and referred to the study by [CONTACT_105129] 
S.M.A.R.T. Project Page 31 of 147  version 1.1  
01 March 2021 
 counselors. Parents may also respond to study advertisements (e.g., UNC campus-wide email, 
posted flyers). 
 Study staff will contact [CONTACT_105130]’s parents and, with permission, conduct an initial 
telephone screen with the adolescent. 
 Information describing the study will be sent to the parent for sharing with the adolescent. 
 Adolescents will be sent a link to the QIDS-SR assessment through REDCap. Study staff will 
review QIDS-SR scores. Participants with scores of at least 6 are considered eligible for a 
baseline psychological evaluation. 
 A baseline psychological evaluation will occur within 5 weeks of screening. If the baseline 
psychological evaluation cannot be scheduled within this timeframe, the adolescent should 
retake the screening questionnaire to assure continued eligibility. 
 After consenting, a parent and the adolescent will meet with the study psychologist for the 
baseline psychological evaluation using the in-person Diagnostic Interview Schedule for 
Children (DISC-IV), including assessment of eligibility criteria. 
 The Study Psychologist notifies the study team of the adolescent’s eligibility for the class.  
Eligible participants will start the class within [ADDRESS_116725]. 
6.2.2: Enrollment, Baseline, and/or Randomization 
The enrollment procedures and baseline assessments will constitute Visit 1. 
Enrollment 
Study enrollment will occur at the time the parent signs the informed consent and the adolescent signs 
the assent form. Section 4.3.[ADDRESS_116726] will evaluate the adolescent’s eligibility for the program and notify study team personnel of 
eligibility. 
Randomization 
After the first two groups (one each of MFY and HLG),  randomization occurs one week before the first 
class. A designated study team member will use the randomization feature of REDCap to randomize 
participants. The procedure involves a review of eligibility followed by [CONTACT_105131].  
6.2.3: Follow-up Visits 
Following the eight-week program, participants will have self-report assessments 22 weeks after the 
program (Visit 13) and 36 weeks after the program (Visit 16, final evaluation). 
Master Protocol 
S.M.A.R.T. Project Page 32 of 147  version 1.1  
01 March 2021 
 Visit 1 
Section 6.2.2 , Enrollment  and Baseline Assessments , provides a description of Visit 1.   
Visit 2 
Study staff will send the study questionnaires via a link to parents and adolescents one week before the 
start of classes. Parents and adolescents will complete the online measures. Once measures are 
completed, study staff will notify the participants of their group assignment and logistics of participation 
(time, place, etc.) 
Visits 3-10 (8 weeks of Classes) 
Adolescents attend the 8 weeks of classes. Classes will be audio recorded to evaluate the fidelity of the 
instructor to the program.   
Visit 6 (Week 4 of Classes) 
At week 4 of the intervention (Visit 6), adolescents complete a set of questionnaires online.  
Visit 10 (Week 8 of Classes) 
At week 8, adolescents participate in a focus group designed to obtain feedback about the 
program. The focus group will be audio recorded.   
In addition, adolescents complete another set of online questionnaires. Study staff will send a 
link to the study questionnaires to the adolescents and parent one week following completion 
of the 8-week class. See schedule of evaluations  and list of measures  above.  
Visits 11-16 (Continuation Classes—see 6.2.5  for final visit) 
At each continuation class, adolescents will review and practice what they learned in the 8-week classes.  
Both the adolescents and their parents will complete questionnaires [ADDRESS_116727]-intervention (Visit 
13) and [ADDRESS_116728]-intervention (Visit 16). At Visit 16, adolescents will participate in a brief post-
participation interview.  See schedule of evaluations  and list of measures  above . 
6.2.5: Completion/Final Evaluation  
At the end of the continuation phase, participants will complete the final on-line questionnaires.   
Early Discontinuation from Study Intervention 
Potential reasons for early termination include:  
1) Subject no longer interested 
2) Adverse events 
3) Subject not able or willing to follow the protocol 
4) Subject moved away from the area.   
If subjects withdraw early, the PI [INVESTIGATOR_1660] a designee will follow-up by [CONTACT_105132].  
Master Protocol 
S.M.A.R.T. Project Page 33 of 147  version 1.1  
01 March 2021 
 7. SAFETY ASSESSMENTS  
Participant safety is monitored through daily diaries (monitored by [CONTACT_464]), weekly depression 
assessments (PROMIS Pediatric Depression short form), and contact [CONTACT_105133] (weekly 
during program, monthly during continuation phase). Participants exhibiting increased symptoms of 
depression are evaluated by [CONTACT_105134]. Further details 
on safety are found in the study’s Data Safety Monitoring Plan (DSMP, Appendix IV ). 
7.1: Specification of Safety Parameters 
Combined SMFQ-C / SMFQ-P scores of 12 is the recommended cut-off value for MDD; this value or 
greater will generate follow-up with the study psychologist. In addition, a T score of [ADDRESS_116729]. 
7.2: Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters 
1) Timing: every contact [CONTACT_105135].  
2) Recording: each incidence of an adverse event will be recorded in REDCap. 
3) Analyzing: the PI [INVESTIGATOR_105076] (ISMC) (See DSMP). 
7.3: Adverse Events and Serious Adverse Events  
Adherence to current definitions and submission guidelines for identification and reporting to the IRB of 
Adverse Events (AEs), including Serious AEs (SAEs), and Unanticipated Problems (UPs) is planned. 
Reporting of all adverse events will be the responsibility of the PI ([CONTACT_105158]). The project 
manager and research assistant will assist the PI [INVESTIGATOR_105077], recording, and reporting all AEs. The 
PI [INVESTIGATOR_105078]. 
Subjects will be encouraged to report, in a timely fashion, any incidents of discomfort, or a change in 
health status for any reason, to the research personnel.  
It will be the responsibility of the PI, with assistance from the project manager and research assistant, to 
respond to IRB directives growing out of adverse events, including but not limited to, development and 
implementation of corrective action plans. The reporting process has recently been streamlined and 
made available online to investigators. It is also the responsibility of the PI [INVESTIGATOR_105079], at times, in advance of IRB review of the incident.  
7.3.1: Definitions 
An adverse event (AE) is any untoward medical occurrence in a subject during participation in a clinical 
study or with use of the experimental agent being studied. An adverse finding can include a sign, 
symptom, abnormal assessment (laboratory test value, vital signs, electrocardiogram finding, etc.), or 
any combination of these regardless of relationship to participation in the study. 
A serious adverse event (SAE) is any AE that results in one or more of the following outcomes: 
Master Protocol 
S.M.A.R.T. Project Page 34 of 147  version 1.1  
01 March 2021 
  Death 
 A life-threatening event 
 Inpatient hospi[INVESTIGATOR_1081]  
 A persistent or significant disability/incapacity 
 A congenital anomaly or birth defect 
 An important medical event based upon appropriate medical judgment 
7.3.2: Classification of AE Severity 
Classification of AEs will be based on the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4, 2009. AEs will be described by [CONTACT_105136]/diagnosis, and graded for severity (mild, 
moderate, or severe) ― depending on the intensity of the event.  Two additional categories will be used 
based on the CTCAE system, “life threatening” and “death”.  
Grade 1.  Mild: asymptomatic or mild symptoms; clinical or diagnostic observations only; minimal impact 
on subject’s life; intervention not indicated.  
Grade 2. Moderate: medical care sought; significant but limited inconvenience on Activities of Daily 
Living (ADL) or lifestyle; local or noninvasive intervention indicated. 
Grade 3. Severe: medically significant but not immediately life-threatening; disabling; limiting self-care; 
substantial disruption to the subject’s well-being; hospi[INVESTIGATOR_48622]. 
Grade 4. SAE. Life-threatening consequences; urgent medical intervention indicated.  
Grade 5. SAE. Death: related to AE.  
An AE that is graded as severe (Grade 3) can be distinct from an SAE (Grades 4 and 5). A subject could 
experience a severe AE (Grade 3) that does not meet the definition of an SAE (see above). Alternatively, 
a subject could experience a moderate AE (fever, mild confusion) that meets the SAE definition 
(example - need for antibiotics to combat a life threatening infection).  
7.3.3: AE Attribution Scale  
AEs will also be classified on an assessment of relatedness to the study intervention. AEs will be 
categorized according to the likelihood that they are related to the study intervention. They will be 
labeled as: 1) definitely related, 2) definitely unrelated, 3) probably related, or 4) possibly related to the 
study intervention in the opi[INVESTIGATOR_105080].  
7.4: Reporting Procedures 
No events will be solicited.  Unsolicited events will be captured by [CONTACT_105137].  
A dated log of AEs, UPs, and SAEs will be kept in the study database. Data captured will include a 
detailed description of each incident, experience, or outcome.  In addition, staff will include an 
explanation of why the AE, incident, experience, or outcome is considered a UP.  The PI [INVESTIGATOR_105081] 
S.M.A.R.T. Project Page 35 of 147  version 1.1  
01 March 2021 
 proposed in response to a UP. 
To satisfy the requirement for prompt reporting, unanticipated problems will be reported using the 
following timeline:   
 Unanticipated problems that are serious adverse events will be reported to NCCIH within 7 days 
of the investigator becoming aware of the event.  
 The PI, within 24 hours, will report all related or possibly-related AND serious adverse events 
(SAE) occurring in subjects to the IRB. This will be accomplished by [CONTACT_105138]. Serious adverse events will be reported even if the PIs and 
Study Psychologist believe that the adverse events are unrelated to the protocol. 
 
 Unexpected (but not serious) adverse events occurring in subjects which, in the opi[INVESTIGATOR_105082], are possibly related to participation AND place subjects or others at a 
greater risk of harm than was previously known or recognized in the protocol will be reported by 
[CONTACT_978] [INVESTIGATOR_874] 24 hours of discovery by [CONTACT_105139]. A follow-up 
written report within 5 business days to the IRB and the ISMC will be submitted by [CONTACT_978]. 
 
 Unanticipated problems involving risks to subjects or others (UPI[INVESTIGATOR_16104]) will be reported to the 
IRB and DSMB via email or telephone within 24 hours of discovery and a written follow up 
report within 5 business days. 
 
 Any other unanticipated problem will be reported to the IRB, Independent Safety Monitor(s), 
and NCCIH within 14 days of the investigator becoming aware of the problem.  
 
 When a protocol deviation occurs, the investigator will report the occurrence to the IRB. The 
investigator will make the determination whether the deviation meets the criteria for an 
unanticipated problem involving risks to subjects or others. The IRB Chair or IRB staff member 
will also make the determination if the protocol deviation meets the definition of an 
unanticipated problem involving risks to participants or others. 
 
All unanticipated problems will be reported to appropriate institutional officials (as required by [CONTACT_8706]’s written reporting procedures), the supporting agency head (or designee), and OHRP within 
one month of the IRB’s receipt of the report of the problem from the investigator. 
SAEs that are unanticipated, serious, and possibly related to the study intervention will be reported to 
the Independent Safety Monitor(s), IRB, and NCCIH in accordance with requirements.   
 Unexpected fatal or life-threatening AEs related to the intervention will be reported to the 
NCCIH Program Office, and ISMC within 3 days of the investigator becoming aware of the 
event.  Other serious and unexpected AEs related to the intervention will be reported within 
7 days. 
 Anticipated or unrelated SAEs will be handled in a less urgent manner but will be reported 
to the Independent Safety Monitor(s), IRB, and other oversight organizations in accordance 
with their requirements and will be reported to NCCIH on an annual basis.    
Master Protocol 
S.M.A.R.T. Project Page 36 of 147  version 1.1  
01 March 2021 
  All other AEs documented during the course of the trial will be reported to NCCIH on an 
annual basis by [CONTACT_105140].  The Independent Safety 
Monitor(s) Report will state that all AEs have been reviewed. 
 All AEs documented during the course of the trial will be reviewed by [CONTACT_105141] (ISMC) on a regular basis.  The ISMC will meet initially after 
the first cohort (20) subjects have completed the intervention and are in the continuation 
phase of the study.  The ISMC will meet every [ADDRESS_116730] population.   
7.5: Follow-up for Adverse Events 
The Study Psychologist will investigate AEs related to participant mental health and make appropriate 
referrals for further care. The Study Psychologist will follow-up with the parent to assess follow-through 
within one week of the reported event. The Project Manager will investigate all other AEs and follow up 
with the participant until stable. 
7.6: Safety Monitoring (See DSMP ) 
An Independent Safety Monitoring Committee (ISMC) will be constituted with a charter describing 
membership, meeting frequency, review process, report generation, liaison with the PI [INVESTIGATOR_105083], range of recommendations and criteria for subject removal and program suspension.  
ISMC membership should include: a psychologist with expertise in depression, a 
psychologist/psychiatrist with a research/statistical background, and an individual with expertise in 
mindfulness.  None of these individuals will be directly associated with the study other than through the 
ISMC.  
7.6.1: Frequency of Review   
The ISMC will meet prior to the first group trainings, and within one month after the first full cohort of 
20 subjects (10 in each group) have completed the [ADDRESS_116731] as requested. The ISMC will continue to meet through data collection. 
7.6.2: Review Materials  
The ISMC will review all available data sets, AEs, SAEs and UPs, operational manuals, focus group 
reports, IRB submissions and renewal documentation, IRB notifications and all other materials 
generated by [CONTACT_1758].  
Master Protocol 
S.M.A.R.T. Project Page 37 of 147  version 1.1  
01 March 2021 
 7.6.3: Summary report   
A member of the ISMC will be designated by [CONTACT_105142] a report after each meeting, summarizing the review along 
with recommendations for changes, if any, and continuation of the project. The report will be 
transmitted to the PI [INVESTIGATOR_874] [ADDRESS_116732], requiring action.   
8. INTERVENTION DISCONTINUATION  
8.1:  Discontinuation of Intervention for a Participant 
Subject may stop their participation for any reason, e.g., the subject is non-compliant with the protocol; 
subject develops unacceptable side effects; or psychosocial circumstances prevent continuation.    
8.2: Possible reasons for discontinuation of the whole study   
Possible reasons for discontinuation of the whole study include the following:   
 Study closure by [CONTACT_105143] 
 Research environment is no longer supportive 
 Multiple Unexpected Problems (UP) 
 Insufficient recruitment 
 ISMC or Study Monitor find evidence of serious safety issues. If greater than 3 enrolled and 
randomized subjects develop a grade 3 or greater adverse event due to the intervention, the 
entire study would be stopped and the ISMC will reevaluate. 
8.3: Early discontinuation  
Participants will continue to be followed, with their permission, for another 6 weeks if study 
interventions are discontinued for reasons other than the normal end of the study. Permission will be 
sought for questionnaire completion at stoppi[INVESTIGATOR_007].    
8.4: Normal end to the study  
At the end of the 8-week intervention, subjects completing that part of the study will be followed for 
another [ADDRESS_116733]-intervention (Visit 13) and [ADDRESS_116734] intervention (Visit 16). 
9. STATISTICAL CONSIDERATIONS  
9.1: General Design Issues  
This study is a planning grant for development of an adequately powered clinical trial. Statistical 
hypotheses are not considered relevant to this mechanism. Randomization is designed to assess 
feasibility of our randomization plan, in addition to general feasibility issues of the delivery of the 
educational programs.  
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116735] aim, we proposed exploratory analysis of clinical outcomes (see below). 
9.2: Sample Size and Randomization 
9.2.1: Treatment Assignment Procedures 
Participants are randomized to treatment assignments to test the acceptability of randomization in the 
population. Random allocation, stratified by [CONTACT_547], is assured by a computer-generated assignment 
accessible to the REDCap administrator, but group assignment cannot be masked, except to quantitative 
data analysts.   
Power and sample size. Untreated, >30% of adolescents are expected to develop incident depression. 
Power is calculated for time to incident MDD. With a sample size of 80, we expect to have 80% power to 
detect a hazard ratio of 0.52 for time to MDD between the groups. It is anticipated that we will screen 
160 with the QIDS and 120 with the DISC to achieve a sample of 80 eligible teens (with 80 parents). Our 
target recruitment estimate is [ADDRESS_116736] the involvement of one parent. 
9.3: Definition of Populations 
The ITT (Intent to treat) population is any participant randomized to an intervention group, whether or 
not he/she participates. “Per protocol” populations (“Completers”) are participants who do not formally 
withdraw. 
9.4: Interim Analyses and Stoppi[INVESTIGATOR_1869] 
9.4.1: Study-wide stoppi[INVESTIGATOR_105084] a serious adverse event, CTCAE Grade 3 or higher, possibly related to 
the study protocol, occurring in 5 or more randomized adolescents. If these conditions occur, the ISMC 
will review and make recommendations on the advisability of continuing the study 
9.4.2: Individual stoppi[INVESTIGATOR_105085] a participant scores above 12 on the combined parent and child SMFQ at any point in the study, s/he 
will be referred to the study psychologist ([CONTACT_19230]-Britt) within [ADDRESS_116737] the parent of the teen (within 24 hours) to inform the parent of the depression status of 
the teen. [CONTACT_19230]-Britt will make an evaluation to determine if s/he can continue in the study and will 
refer the family for appropriate psychological care. 
We have added a safety depression screening measure, the PROMIS pediatric depression scale, which 
will be administered weekly via REDCap. The Assessment Center at NIH provides a scoring algorithm 
with REDCap software, enabling use of the measure for safety monitoring. The Project Manager or 
trained designee will monitor these measures weekly and will alert the team (including the Study 
Psychologist) to sharp increases in depressive symptoms and depressive symptoms meeting criteria for 
major depression. If the Study Psychologist confirms the development of major depression, the 
adolescent will be withdrawn from the study and referred for further care. 
Master Protocol 
S.M.A.R.T. Project Page 39 of 147  version 1.1  
01 March 2021 
 9.4.3: Additional Reasons for Withdrawal of a Participant  
Additional reasons a participant may withdraw from the study include: 
 The adolescent wishes to withdraw from the study; 
 Loss of study eligibility (development of major depression); 
 Intervening illness or injury making participation difficult; 
 The adolescent develops any condition that, in the opi[INVESTIGATOR_105086], would 
make continued participation unsafe. 
In the unlikely event that a participant is unable to participate in a group setting, s/he may be withdrawn 
from the study. 
9.5: Outcomes  
Our primary goal is to develop a depression-prevention program based on mindfulness and self-
compassion and to establish the feasibility of its implementation as compared with an active attention-
control comparator. Hence, the establishment of quality assurance processes and complete data 
documentation assume even greater importance than data analysis. Data of multiple types from 
multiple sources will be captured. For questionnaire assessments, secure internet-based data collection 
instruments will be used, accessible by [CONTACT_105144]-capable device.  
Quality assurance of these measures will include review of study instruments for range and consistency 
checks, and descriptive analyses to assess distributions of study variables. Quality assurance of 
qualitative measures include 1) maintaining a spreadsheet to log scheduled, completed, transcribed, and 
analyzed focus groups and interviews; 2) establishing a transcription template to ensure data is uniform 
in appearance; 3) arranging for secure storage of recordings and transcripts on REDCap; 4) review of 
consistency of styles across interviewers; and 5) review of recordings to assess accuracy of 
transcriptions.  
All statistical analyses will utilize all adolescents who were randomized to one of the intervention arms 
and who attended at least one class.  Individuals who were unable to attend a class are excluded.  
Complete case analyses are planned (without imputations).   
9.5.1: Primary Outcome   
For the primary outcome, (to be explored as described in Specific Aim 3, once feasibility is examined in 
Specific Aim 2), a score of 70 on the PROMIS Pediatric Depression Scale short form t-score. To assess 
incident depression, we will use exploratory nonparametric (Kaplan-Meier plots) and semi-parametric 
analyses (Cox proportional hazards models) to examine the trends in incident depression within and 
between treatment arms.  If too few students reach the target of 70 ([ADDRESS_116738] deviations above the 
population mean), we will explore outcomes using a target of 65 (1.[ADDRESS_116739] deviations above the 
population mean).  We had originally planned to use the SMFQ, but the SMFQ was collected only 5 
times for those with complete data and the PROMIS Depression score was collected weekly, making it a 
much more reasonable measure for a time-to-event analysis. 
9.5.2: Secondary Outcomes   
For the secondary outcome, assuming feasibility is established, change in the Short Mood and Feelings 
Questionnaire (child and parent versions) will be examined in a linear regression in each condition, to 
test for any effect of either program. Then we will examine the change in depression scores through an 
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116740], and a cohort*time interaction—to allow the trajectory to 
vary by [CONTACT_9084]—as well as random effects for individual subjects and subjects nested within cohorts. 
Between program arms, we would add terms for the program arm and its interaction with time. 
9.6: Data Analyses  
9.6.[ADDRESS_116741] significant effects of the MFY program compared to the TFY control program.  However, 
trends in incident depression (primary outcome, PROMIS Pediatric Depression Scale), change in 
depression scores (combined SMFQ-C, PROMIS Pediatric Depression Score) resilience (secondary 
outcome), and potential mediators will be examined by [CONTACT_105145]. 
To assess incident depression, we will use exploratory nonparametric (Kaplan-Meier plots) to examine 
the trends in incident depression within and between treatment arms using the PROMIS Pediatric 
Depression Scale short-form..   
To address the change in depressive symptoms (secondary outcome), we will examine the paired t-test 
in each condition, to test for any effect of either program.  Subsequently, an exploratory analysis will 
examine the trajectory of changes over time by [CONTACT_105145], using graphical representations of 
outcomes at each time point by [CONTACT_1130], cohort, and program arm as well as longitudinal random effects 
models. Hence, a within-group model would include terms for the follow-up depression score, the 
overall intercept, the cohort effect, the time effect, and a cohort*time interaction—to allow the 
trajectory to vary by [CONTACT_9084]—as well as random effects for individual subjects and subjects nested 
within cohorts.  
Additional explorations will include bivariable associations (correlation, simple regressions) between the 
process measures and the outcome, between intervention assignment and process measures, between 
intervention assignment and potential mediators, and between process measures and outcomes. If 
indicated, mediation analyses will be conducted to investigate possible mechanisms; strength of 
mediation (indirect effect) will be calculated as the product of the association of the causal variable on 
the mediator and the association of the mediator on the outcome variable.      
9.6.2:  Feasibility Analyses 
Feasibility will be measured by [CONTACT_716]:   
1. Acceptance of the treatment and control programs as measured by [CONTACT_105146] 6 of 8 active 
intervention sessions and 4 of 6 continuation sessions;  
2. Equivalence of the credibility of the two programs as measured with the credibility 
questionnaire;  
Master Protocol 
S.M.A.R.T. Project Page 41 of 147  version 1.1  
01 March 2021 
 3. Identification of recruitment challenges and their remedies as measured by:  
a. the number of individuals screened;  
b. the proportion of screened adolescents who qualify;  
c. the number of qualifiers who enroll; and d) the number of enrollees who complete the 
program—80% completion defined by [CONTACT_105147] a feasible 
program;  
4. Identification of factors associated with subjects’ willingness to adhere to the study protocol 
such as:  
a. Location or timing of program classes, or lack of transportation;  
b. Those not completing the program will be contact[CONTACT_5365] a telephone interview to 
evaluate factors leading to dropout.  
5. Identification of study components fostering engagement in the study groups and materials. 
Subject Engagement 
In addition to attendance data, engagement will be measured by: 
1. Subjective class participation as rated by [CONTACT_105148];  
2. Adherence to recommended homework practice as measured in the daily diary; 
3. Barriers for practice as captured in the diary; 
4. Participant comments about the degree to which these practices have enabled them to 
adopt an attitude of mindfulness and self-compassion (as captured in the audio-taped 
class sessions). At the end of participation in the study, at month 8-9, subjects will be 
invited to give their impressions about the study in a brief, post-participation focus 
group or interview (see Section 5.1.3, Qualitative Measures ).  
Program Fidelity 
All program sessions will be audio-recorded. The purpose of the recording is two-fold: 
1. To identify any systematic variations in instructors’ attitude, communication, or 
behavior between treatment groups; to assess adherence to the protocol; and to screen 
for any group-dependent differences in communication in content or style between the 
instructors and subjects; 
2. To capture participants’ input and comments during the classes (see qualitative 
analysis).  
An evaluation matrix will be developed based on the program manuals and other written protocols.  
Two members of the study staff will listen to selected program sessions independently to rate 
adherence to the protocol.   
Program Credibility 
Credibility is measured by [CONTACT_105149].   
 
Acceptance of randomization is measured by a comparison of drop-out rates by [CONTACT_105150] . 
Master Protocol 
S.M.A.R.T. Project Page 42 of 147  version 1.1  
01 March 2021 
 10. DATA COLLECTION AND QUALITY ASSURANCE 
10.1: Data Collection: Data Type, Personnel Collecting Data 
Project Manager and Research assistants:   
 Entering screening data.   
 Prompting questionnaire completion by [CONTACT_105151].   
 Reminding teens to complete daily/weekly homework assignment assessments and 
depression screens.  
The study psychologist or a member of her practice will collect eligibility data. 
10.2: Data Management  
Data resulting from telephone screening is housed in a screening database on REDCap. The research 
assistant will enter screening data directly into REDCap.  
After consenting, the participant is added to the study REDCap database as an enrolled subject. The 
study psychologist will notify study staff if the participant remains eligible for the study after evaluation.  
This information will be added to the study database as eligible or ineligible at baseline (to protect 
participant privacy).   
Online data collection forms are developed by [CONTACT_105152]. Participants and their 
parents enter this questionnaire data directly into REDCap. 
10.3: Quality Assurance  
10.3.1: Training 
Current HIPAA and CITI training (Human Research Ethics, Good Clinical Practice) certificates are required 
of all study personnel who will be recruiting subjects, evaluating subjects, collecting or analyzing data. 
Before participant data is collected, the PI [INVESTIGATOR_105087]. A log including dates and type of training will be kept in section 10 of the 
Study Regulatory Binder. 
The Study Manual of Operating Procedures (MOP) will include detailed procedures for each of the 
following: 
 Consent forms: 
o Telephone/screening (with detailed script and instructions included) 
o Full Consent (parental permissions and assents)  
o HIPAA Consent 
o Social Security Collection for Payments 
 Study visit procedures including advising participants in collection of questionnaire and diary 
data 
Master Protocol 
S.M.A.R.T. Project Page 43 of 147  version 1.1  
01 March 2021 
  Advising participants on use of the study app 
10.3.2: Quality Control Committee  
The quality control committee consists of the project manager, the internal QA Reviewer (Faurot), and 
the study statistician (Suchindran). Monthly reports are made to the committee and PI [INVESTIGATOR_105088].   
10.3.3: Metrics 
Diary Data  
Participants will complete daily diaries during the [ADDRESS_116742] not completed their diaries by 4:00 PM. 
Self-report Questionnaires   
Questionnaires will be completed at baseline (Visit 2) and at weeks 4 (Visit 6), 8 (Visit 10), 22 (about 22 
weeks after the intervention; Visit 13), and 36 (about 36 weeks after the intervention ends; Visit 16). 
Participants will complete the questionnaires via a link to the survey mechanism on REDCap, accessing 
the site through a password-protected interface. The questionnaires prompt participants to complete 
skipped items and they must confirm that they wish to skip an item.  After the participant completes the 
questionnaire, study team personnel will access the REDCap site and check the entries for completeness 
to ascertain any computer or questionnaire malfunction. Study team will keep paper copi[INVESTIGATOR_105089].   
Questionnaires designed to be completed on paper (Expectation of Benefit/Credibility), will be made 
available to participants at the first class, collected by [CONTACT_17033], and entered (twice) into 
REDCap. The paper copy will be saved in the participant’s study folder to be used for corrections as 
needed.  An error rate of greater than 1% will generate additional training. 
10.3.4: Protocol Deviations 
Staff will be trained to record any protocol deviation that may occur while performing their specific 
research related activities. Many of the data collection forms include comment sections where protocol 
deviation information will be captured on the source documents. Deviations will also be documented in 
the Study Regulatory Binder, section 12, and on REDCap. Training of the research staff will include 
practices of double checking all demographics, inclusion/exclusion criteria, data collection procedures 
including capture and secure storage, intervention procedures and data management activities.   
Deviations will be documented as a written report submitted to the UNC IRB by [CONTACT_978] [INVESTIGATOR_105090]. New deviations will be presented by [CONTACT_105153]. Corrective action plans will be developed and 
submitted to the IRB as part of that reporting process.  
10.3.5: Monitoring 
The PI [INVESTIGATOR_105091]. The logs and reports of these visits are kept in the Study Regulatory Binder. 
Master Protocol 
S.M.A.R.T. Project Page 44 of 147  version 1.1  
01 March 2021 
 11. PARTICIPANT RIGHTS AND CONFIDENTIALITY  
11.1: Institutional Review Board (IRB) Review  
This protocol and the informed consent document ( Appendix I ) and any subsequent modifications will 
be reviewed and approved by [CONTACT_105154]. The IRB application, 
modification and renewal procedures will be adhered to throughout the study.  
11.2: Informed Consent Forms 
A signed parental informed consent form and a signed participant assent form will be obtained for each 
participant if the teen participant is under 18, and a consent form from the teen participant if the 
participant turns 18. 
The consent form will describe the purpose of the study, the procedures to be followed, reasons not to 
be in the study, the risks and benefits of participation, responsibilities of the participant, incentives and 
remunerations, privacy and confidentiality measures, and the name [CONTACT_3669] [CONTACT_71722] 
[INVESTIGATOR_105092]. The participant will be given the opportunity to read the Informed Consent and ask 
questions regarding the study. If they have their questions answered and are willing to participate, the 
informed consent and informed assent will be signed at this meeting and also signed by [CONTACT_105155]. A copy of the IFC and the IFA will be given to each participant. 
11.3: Participant Confidentiality  
Participant confidentiality will be maintained according to the Health Insurance Portability and 
Accountability Act (HIPAA). All records will be kept in a locked file cabinet. All data will be stored on 
password-protected computers in an encrypted database. 
11.4: Study Discontinuation  
The study may be discontinued at any time by [CONTACT_1201], the NCCIH, the OHRP, the FDA, or other 
government agencies as part of their duties to ensure that research participants are protected.  
12. COMMITTEES 
An Independent Safety Monitoring Committee (ISMC) will be formed. Refer to Section 7.6: Safety 
Monitoring  and Appendix IV  for details about the ISMC. 
13. PUBLICATION OF RESEARCH FINDINGS 
Research findings will be published in ClinicalTrials.gov and in the scientific literature.  A poster 
documenting the development of the Healthy Lifestyles Group has already been presented at the 
American Public Health Association Meeting in 2019. 
14. REFERENCES  
1. Kessler R, Avenevoli S, Merikangas KR. Mood disorders in children and adolescents: An 
epi[INVESTIGATOR_46235]. Biological Psychiatry. 2001;49:1002-1014. 
Master Protocol 
S.M.A.R.T. Project Page 45 of 147  version 1.1  
01 March 2021 
 2. Johnson D, Greenberg MT. Parenting and early adolescence internalizing: The importance of 
teasing apart anxiety and depressive symptoms. Journal of Early Adolescence. 2013;33:201-226. 
3. Rudolph KD. Adolescent depression. In: Gottlib IH, Hammon CL, eds. Handbook of depression . 
2nd ed. [LOCATION_001]: Guilford Press; 2009. 
4. Hammon C, Rudolph K. Childhood mood disorders. In: Mash EJ, Barkley RA, eds. Child 
psychopathology . [LOCATION_001], NY: Guilford; 2003:233-278. 
5. Albano AM, Chorpi[INVESTIGATOR_105093], Barlow DH. Childhood anxiety disorders. In: Mash EJ, Barkley RA, eds. 
Child psychopathology [LOCATION_001], NY: Guilford; 2003:279-329. 
6. Crocetti E, Klimstra T, Keijsers L, Hale WW, Meeus W. Anxiety trajectories and identity 
development in adolescence: A five-wave longitudinal study. Journal of Youth and Adolescence. 
2009;38:839-849. 
7. Costello EJ, Pi[INVESTIGATOR_29835], Hamen C, et al. Development and natural history of mood disorders. 
Biological Psychiatry. 2002;52:529-542. 
8. Weissman MM, Wolk S, Goldstein RB, et al. Depressed adolescents grown up. Journal of the 
American Medical Association. 1999;281:1707-1713. 
9. Stice E, Shaw H, Bohon C, Marti CN, Rohde P. A meta-analytic review of depression prevention 
programs for children and adolescents: factors that predict magnitude of intervention effects. 
Journal of consulting and clinical psychology. Jun 2009;77(3):486-503. 
10. Greeson JM. Mindfulness Research Update: 2008. Complementary Health Practice Review 2009. 
2009;14(10):10-18. 
11. Grossman P, Niemann L, Schmidt S, Walach H. Mindfulness-based stress reduction and health 
benefits - A meta-analysis. Journal of psychosomatic research. Jul 2004;57(1):35-43. 
12. Hofmann SG, Sawyer AT, Witt A, Oh D. The effect of mindfulness-based therapy on anxiety and 
depression: A meta-analytic review. Journal of consulting and clinical psychology. 
2010;78(2):169-183. 
13. Raes F. The Effect of Self-Compassion on the Development of Depression Symptoms in a Non-
clinical Sample. Mindfulness. 2011;2(1):33-36. 
14. Neff KD, Germer C. A pi[INVESTIGATOR_105094]-compassion 
program. Journal of Social and Clinical Psychology. 2013. 
15. Brown K, West, Loverich, Biegel. Assessing adolescent mindfulness: Validation of an adapted 
Mindful Attention Awareness Scale in adolescent normative and psychiatric populations. 
Psychological assessment. 2011. 
16. Greco L, Baer RA, Smith GT. Assessing mindfulness in children and adolescents: Development 
and validation of the child and adolescent mindfulness measure (CAMM). Psychological 
assessment. 2011;23(3):606-614. 
Master Protocol 
S.M.A.R.T. Project Page 46 of 147  version 1.1  
01 March 2021 
 17. Biegel G, Brown K, Shapi[INVESTIGATOR_2152] S, Schubert C. Mindfulness-based stress reduction for the treatment 
of adolescent psychiatric outpatients: A randomized clinical trial. Journal of Clinical and 
Consulting Psychology. 2009;77(5):855-866. 
18. Broderick P. Learning to BREATHE: A mindfulness curriculum for adolescents. Pennsylvania State 
University; 2010. 
19. Schonert-Reichl KA, Lawlor MS. The effects of a mindfulness-based education program on pre- 
and early adolescents’ well-being and social and emotional competence. Mindfulness. 
2010;1(3):137-151. 
20. Zeller M, Yuval K, Nitzan-Assayag Y, Bernstein A. Self-compassion in recovery following 
potentially traumatic stress: Longitudinal study of at-risk youth. Journal of abnormal psychology. 
in press. 
21. Barry CT, Loflin DC, Doucette H. Adolescent self-compassion: Associations with narcissism, self-
esteem, aggression, and internalizing symptoms in at-risk males. Journal of Personality and 
Individual Differences. 2015;77:118-123. 
22. Bluth K, Blanton P. Mindfulness and self-compassion: Exploring pathways of adolescent 
wellbeing. Journal of Child and Family Studies. 2014; 23 (7):1298-1309. 
23. Neff KD, McGehee P. Self-compassion and psychological resilience among adolescents and 
young adults. Self Identity. 2010;9(3):225-240. 
24. Bluth K, Blanton P. The influence of self-compassion on emotional well-being among early and 
older adolescent males and females                   Journal of Positive Psychology. 2014. 
25. Kabat-Zinn J. Full Catastrophe Living.  [LOCATION_001]: Random House; 1990. 
26. Neff KD. Self-compassion: An alternative conceptualization of a healthy attitude toward oneself. 
Self Identity. 2003;2:85-101. 
27. Clarke GN, Hornbrook M, Lynch F, et al. A randomized trial of a group cognitive intervention for 
preventing depression in adolescent offspring of depressed parents. Archives of General 
Psychiatry. Dec 2001;58(12):1127-1134. 
28. Administration SAaMHS. Behavioral Health Barometer: [LOCATION_002], 2014. HHS Publication No. 
SMA–15–4895.  Rockville, MD: Substance Abuse and Mental Health Services Administration; 
2015. 
29. Angst J, Sellaro R, Merikangas KR. Depressive spectrum diagnoses. Comprehensive psychiatry. 
2000;41:39-47. 
30. Frojd SA, Nissinen ES, Pelkonen MU, Marttunen MJ, Koivisto AM, Kaltiala-Heino R. Depression 
and school performance in middle adolescent boys and girls. J Adolesc. Aug 2008;31(4):485-498. 
31. Hauenstein EJ. Depression in Adolescence. Journal of Obstetric, Gynecologic, and Neonatal 
Nursing. 2003;32(2):239-248. 
32. Deykin EY, Levy JC, Wells V. Adolescent depression, alcohol and drug abuse. American journal of 
public health. 1987;77:178-182. 
Master Protocol 
S.M.A.R.T. Project Page 47 of 147  version 1.1  
01 March 2021 
 33. Fergusson DM, Boden JM, Horwood LJ. Recurrence of major depression in adolescence and early 
adulthood, and later mental health, educational and economic outcomes. The British journal of 
psychiatry : the journal of mental science. Oct 2007;191:335-342. 
34. Saluja G, Iachan R, Scheidt PC, Overpeck MD, Sun W, Giedd JN. Prevalence of and risk factors for 
depressive symptoms among young adolescents. Archive of Pediatric and Adolescent Medicine. 
2004;158:760-765. 
35. Naicker K, Galambos NL, Zeng Y, Senthilselvan A, Colman I. Social, demographic, and health 
outcomes in the 10 years following adolescent depression. J Adolesc Health. May 
2013;52(5):533-538. 
36. Richardson LP, Davis R, Poulton R, et al. A longitudinal evaluation of adolescent depression and 
adult obesity. Archives of Pediatric and Adolescent Medicine. 2003;157:739-745. 
37. Lovato N, Gradisar M. A meta-analysis and model of the relationship between sleep and 
depression in adolescents: Recommendations for future research and clinical practice. Sleep 
Medicine Review. (in press). 
38. Gotlib IH, Lewinsohn PM, Seeley JR. Consequences of depression during adolescence: Marital 
status and marital functioning in early adulthood. Journal of Abnormal  Psychology. 
1998;107:686-690. 
39. Lewinsohn PM, Solomon A, Seeley JR, Zeiss A. Clinical implications of subthreshold depressive 
symptoms. Journal of Abnormal  Psychology. 2000;109:345-351. 
40. Keenan-Miller D, Hammen CL, Brennan PA. Health outcomes related to early adolescent 
depression. Journal of Adolescent Health. 2007;41:256-262. 
41. Fletcher JM. Adolescent depression: diagnosis, treatment, and educational attainment. Health 
Econ. Nov 2008;17(11):1215-1235. 
42. Fergusson DM, Horwood LJ, Ridder EM, Beautrais AL. Subthreshold depression in adolescence 
and mental health outcomes in adulthood. Arch Gen Psychiatry. Jan 2005;62(1):66-72. 
43. Lewinsohn PM, Rohde P, Klein DN, Seeley JR. Natural course of adolescent major depressive 
disorder: I. Continuity into young adulthood. 38. 1999:56-63. 
44. Pi[INVESTIGATOR_29835], Cohen P, Gurley D, Brook J, Juju M. Consequences of depression during adolescence: 
Marital status and marital functioning in early adulthood. Archive of General Psychiatry. 
1998;55:56-64. 
45. Garber J. Depression in children and adolescents: linking risk research and prevention. American 
journal of preventive medicine. Dec 2006;31([ADDRESS_116743] 1):S104-125. 
46. Hamilton BE, Merrigan P, Dufresne E. Down and out: estimating the relationship between 
mental health and unemployment. Health Economics. 1997;6:397-406. 
47. Kessler R, Foster C, Saunders W, Stang P. Social consequences of psychiatric disorders, I: 
educational attainment. . American Journal of Psychiatry 1995;152:1026–1032. 
Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116744] KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, 
abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. 
Addiction. Jun 2010;105(6):1117-1128. 
49. Divall S, Radovick S. Pubertal development and menarche. Annals of the [LOCATION_001] Academy of 
Sciences. 2008;1135:19-28. 
50. Blakemore J, Berenbaum S, Liben L. Gender development.  Clifton, NJ: Psychology Press; 2009. 
51. Susman E, Dorn L. Puberty: Its role in development. In: Lerner RM, Steinberg L, eds. Handbook of 
adolescent psychology . Third ed. [LOCATION_001]: Wiley; 2009. 
52. Giedd J. The teen brain: Insights from neuroimaging. Journal of Adolescent Health. 2008;42:321-
323. 
53. Keating D. Cognitive and brain development. In: Lerner R, Steinberg L, eds. Handbook of 
adolescent psychology . 2 ed. [LOCATION_001]: Wiley; 2004. 
54. Erikson E. Identity: Youth in crisis.  [LOCATION_001]: Norton; 1968. 
55. Steinberg L. Adolescence.  [LOCATION_001]: McGraw-Hill; 2008. 
56. Elkind D. Egocentrism in adolescence. Child Development. 1967;38:1025-1034. 
57. Elkind D. Egocentrism redux. Developmental Review. 1985;5:218-226. 
58. Reimer MS. "Sinking into the ground": The development and consequences of shame in 
adolescence. Developmental Review. 1996;16:321-363. 
59. Abramson LY, Metalsy GI, Alloy LB. Hopelessness depression: A theory-based subtype of 
depression. Psychological review. 1989;96:358-372. 
60. Gibb BE, Alloy LB, Walshaw PD, Comer JS, Shen GH, Villari AG. Predictors of attributional style 
change in children. J Abnorm Child Psychol. Jun 2006;34(3):425-439. 
61. Abela JRZ, Hankin BL. Cognitive vulnerability to depression in children and adolescents: A 
developmental psychopathology apporach. In: Abela JRZ, Hankin BL, eds. Handbook of child and 
adolescent depression . [LOCATION_001]: NY: Guilford Press; 2008:35-78. 
62. Carter JS, Garber J. Predictors of the first onset of a mojor depressive epi[INVESTIGATOR_105095]: Stress and negative cognitions. Journal of Abnormal  
Psychology. 2011;120(4):779-796. 
63. Lakdawalla Z, Hankin BL, Mermelstein R. Cognitive theories of depression in children and 
adolescents: A conceptual and quantitative review. Clinical Child and Family Psychology Review. 
2007;10:1-24. 
64. Blatt SJ, Zuroff DC. Interpersonal relatedness and self-definition: Two prototypes for depression. 
Clinical psychology review. 1992;12:527-562. 
65. Gilbert P, Irons C. A pi[INVESTIGATOR_105096] a group of 
selfcritical people. Memory. 2004;12:507-516. 
Master Protocol 
S.M.A.R.T. Project Page 49 of 147  version 1.1  
01 March 2021 
 66. Gilbert P, Birchwood M, Gilbert J, et al. An exploration of evolved mental mechanisms for 
dominant and subordinate behaviour in relation to auditory hallucinations in schizophrenia and 
critical thoughts in 
depression. Psychological medicine. 2001. 
67. Hartlage S, Aduino K, Alloy LB. Depressive personality characteristics: State dependent 
concomitants of depressive disorders and traits independent of current depression. Journal of 
Abnormal  Psychology. 1998;107:339-345. 
68. Murphy JM, Nierengberg AA, Monson RR, Laird NM, Sobol AM, Leighton AH. Self-disparagement 
as a feature and forerunner of depression: Findings from the Stirling County study. 
Comprehensive psychiatry. 2002;43:13-21. 
69. Zuroff DC, Moskowitz DS, Cote S. Dependency, self-criticism, interpersonal behaviour and affect: 
Evolutionary perspectives. British Journal of Clinical Psychology. 1999;38:231-250. 
70. Tilghman-Osborne C, Cole DA, Felton JW, Ciesla JA. Relation of guilt, shame, behavioral and 
characterological self-blame to depressive symptoms in adolescents over time 
Journal of Social and Clinical Psychology. 2008;27(8):809-842. 
71. Gilbert P. What is shame? Some core issues and controversies. In: Gilbert P, Andrews B, eds. 
Shame: Interpersonal Behavior, Psychopathology and Culture . [LOCATION_001]: NY: Oxford University 
Press; 1998:3-38. 
72. Gilbert P. Shame and humilation in the treatment of complex cases. In: Tarrier N, Haddock G, 
Wells A, eds. Complex Cases: The Cognitive Behavioural Approach . Chichester: Wiley; 1998:241-
271. 
73. Greenberg LS, Elliot RK, Foester FS. Experiential processes in the psychotherapeutic treatment of 
depression. In: McCann CD, Endler NS, eds. Depression: New directions in theory, research, and 
practice . Toronto: Wall & Emerson, Inc.; 1990:157-185. 
74. Gilbert P. Depression: The Evolution of Powerlessness.  [LOCATION_001]: Lawrence Erlbaum Associates; 
1992. 
75. Tangney JP. Situational Detenninants of Shame and Guilt in Young Adulthood. Personality and 
Social Psychology Bulletin. 1992;18(2):199-206. 
76. Tangney JP, Fischer KW. Self-conscious affect. In: Tangney JP, Fischer KW, eds. Self-conscious 
emotions: Shame, guilt, embarassment, and pride . [LOCATION_001], NY: Guilford Press; 1995. 
77. Gilbert P, Procter S. Compassionate mind training for people with high shame and self-criticism: 
overview and pi[INVESTIGATOR_14737] a group therapy approach. Clinical Psychology and Psychotherapy. 
2006;13(6):353-379. 
78. Tangney JP, Dearing RL. Our "intrapersonal" relationship: The self in shame and guilt. Shame and 
guilt . [LOCATION_001]: Guilford Press; 2002:52-77. 
Master Protocol 
S.M.A.R.T. Project Page 50 of 147  version 1.1  
01 March 2021 
 79. Tangney JP, Wanger PE, Fletcher C, Gramzow R. Shamed into anger? The relation of shame and 
guilt to anger and self-reported aggression. Journal of Personality and Social Psychology. 
1992;62:669-672. 
80. Treynor W, Gonzalez R, Nolen-Hoecksema S. Rumination reconsidered: A psychometric analysis. 
Cognitive Therapy and Research. 2003;27(3):247-259. 
81. Ziegert D, Kistner J. Response styles theory: Downward extension fo children. Journal of Clinical 
Child & Adolescent Psychology. 2002;31:325-334. 
82. Abela JRZ, Brozina K, Haigh EP. An examination of the response styles theory of depression in 
third- and seventh-grade children: A short-term longitudinal study. Journal of Abnormal Child 
Psychology. 2002;30:515-527. 
83. Abela JRZ, Vanderbilt E, Rochon A. A test of the integration of the response styles and social 
support theories of depression in third and seventh grade children. Journal of Social and Clinical 
Psychology. 2004;23(23):653-674. 
84. Schwartz JA, Koenig LJ. Response styles and negative affect among adolescents. Cognitive 
Therapy and Research. 1996;20:13-36. 
85. Smith BW, Dalen J, Wiggins K, Tooley E, Christopher P, Bernard J. The brief resilience scale: 
assessing the ability to bounce back. International journal of behavioral medicine. 
2008;15(3):194-200. 
86. Southwick SM, Vythilingam M, Charney DS. The psychobiology of depression and resilience to 
stress: implications for prevention and treatment. Annual Review of Clinical Psychology. 
2005;1:255-291. 
87. Edward KL. Resilience: A protective factor from depression. Journal of the American Psychiatric 
Nurses Association. 2005;11(4):241-243. 
88. Garber J, Clarke GN, Weersing VR, et al. Prevention of depression in at-risk adolescents: A 
randomized controlled trial. Journal of American Medical Association. 2009;301(21):2215-2224. 
89. Barrett P, Farrell L, Ollendick T, Dadds M. Long-term outcomes of an Australian universal 
prevention trial of anxiety and depression symptoms in children and youth: An evaluation of the 
friends program. Journal of Clinical Child and Adolescent Psychology. 2006;35:401-411. 
90. Bearman SK, Stice E, Chase A. Evaluation of an intervention targeting both depressive and 
bulimic pathology: A randomized prevention trial. Behavior therapy. 2003;34(277–293). 
91. Cardemil EV, Reivich KJ, Beevers CG, E. SM, James J. The prevention of depressive symptoms in 
low-income, minority children: Two-year follow-up. Behavior Research and Therapy. 
2007;45(313–327). 
92. Chaplin TM, Gillham JE, Reivich K, et al. Depression prevention for early adolescent girls: A pi[INVESTIGATOR_105097]-ed groups.  Journal of Early Adolescence. 2006;26:110–126. 
93. Gillham JE, Hamilton J, Freres DR, Patton K, Gallop R. Preventing depression among early 
adolescents in the primary care setting: A randomized controlled study of the Penn Resiliency 
Program. Journal of Abnormal Child Psychology. 2006;34:203–219. 
Master Protocol 
S.M.A.R.T. Project Page 51 of 147  version 1.1  
01 March 2021 
 94. Gillham JE, Reivich KJ. Prevention of depressive symptoms in school children: A research update. 
American Psychological Society. 1999;10:461–462. 
95. Gillham JE, Reivich KJ, Freres DR, et al. School-based prevention of depressive symptoms: A 
randomized controlled study of the effectiveness and specificity of the Penn Resiliency Program. 
Journal of consulting and clinical psychology. Feb 2007;75(1):9-19. 
96. Gillham J, Reivich K, Freres DR, et al. School-based prevention of depression and anxiety 
symptoms in early adolescence: A pi[INVESTIGATOR_16282] a parent intervention component. School Psychology 
Quarterly. 2006;21:323–348. 
97. Horowitz JL, Garber J, Ciesla JA, Young J, Mufson L. Prevention of depressive symptoms in 
adolescents: A randomized trial of cognitive– behavioral and interpersonal prevention 
programs. Journal of consulting and clinical psychology. 2007;75:693–706. 
98. Lowry-Webster H, Barrett P, Lock S. A universal prevention trial of anxiety symptomatology 
during childhood: Results at one year follow-up. Behavior Change. 2003;20:25–43. 
99. Clarke GN, Hawkins W, Murphy M, Sheeber L. Schoolbased primary prevention of depressive 
symptomatology in adolescents: Findings from two studies. Journal of Adolescent Research. 
1993;8:183–204. 
100.  Beardslee W, Gladstone T, Wright E, Cooper A. A familybased approach to the prevention of 
depressive symptoms in children at risk: Evidence of parental and child change. Pediatrics. 
2003;112:119–131. 
101.  Petersen AC, Leffert N, Graham B, Alwin J, Ding S. Promoting mental healthy during the 
transition into adolescence. In: Schulenberg J, Maggs JL, Hierrelmann AK, eds. Health risks and 
developmental transitions during adolescence . [LOCATION_001]: Cambridge University Press; 1997. 
102.  Spence SH, Sheffield JK, Donovan CL. Long-term outcome of a school-based, universal approach 
to prevention of depression in adolescents. Journal of consulting and clinical psychology. 
2005;73:160–167. 
103.  Lamb JM, Puskar KR, Sereika SM, Corcoran M. School-based intervention to promote copi[INVESTIGATOR_105098]. American Journal of Maternal and Child Nursing. 1998;23:187–194. 
104.  Forsyth KM. The design and implementation of a depression prevention program. Dissertation 
Abstracts International. 2000;61(12-B):6704. 
105.  Johnson NC. A follow-up study of a primary prevention program targeting childhood depression.  
Logan, Utah: Utah State University; 2000. 
106.  Sawyer M, Pfeiffer S, Spence S, et al. School-based prevention of depression: A randomized 
controlled study of the BeyondBlue School Research Initiative. Journal of Child Psychology and 
Psychiatry. 2009;51:199-209. 
107.  Stice E, Burton, Bearman SK, Rohde P. Randomized trial of a brief depression prevention 
program: An elusive search for a psychosocial placebo control condition. Behavior Research and 
Therapy. 2006;45:863-876. 
Master Protocol 
S.M.A.R.T. Project Page 52 of 147  version 1.1  
01 March 2021 
 108.  Curry J. Future directions in research on psychotherapy for adolescent depression. Journal of 
Clinical Child and Adolescent Psychology. 2014;43(3):510-526. 
109.  Kabat-Zinn J. Wherever you go, there you are: Mindfulness in Everyday Life.  [LOCATION_001]: Hyperion; 
1994. 
110.  Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression: A new 
approach to preventing relapse.  [LOCATION_001]: Guilford Press; 2002. 
111.  Anderson ND, Lau MA, Segal ZV, Bishop SR. Mindfulness-based stress reduction and attentional 
control. Clinical Psychology and Psychotherapy. 2007;14:449–463. 
112.  Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve 
after mindfulness training: A randomized trial. Neurology. 2010;75:1141–1149. 
113.  Koszycki D, Benger M, Shlik J, Bradwejn J. Randomized trial of a meditation-based stress 
reduction program and cognitive behavior therapy in generalized social anxiety disorder. 
Behaviour research and therapy. Oct 2007;45(10):2518-2526. 
114.  Sephton SE, Salmon P, Weissbecker I, et al. Mindfulness meditation alleviates depressive 
symptoms in women with fibromyalgia: 
Results of a randomized clinical trial. Arthritis and Rheumatism,. 2007;57:77-85. 
115.  Shapi[INVESTIGATOR_2152] S, Schwartz G, Bonner G. Effects of mindfulness-based stress reduction on medical and 
premedical students. Journal of Behavioral Medicine 1998;21(6):581-599. 
116.  Speca M, Carlson LE, Goodey E, Angen M. A randomized, wait-list controlled clinical trial: The 
effect of a mindfulness meditation-based stress reduction program on mood and symptoms of 
stress in cancer outpatients. Psychosomatic medicine. 2000;62:613-622. 
117.  Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and 
depression: A meta-analytic review. Journal of consulting and clinical psychology. Apr 
2010;78(2):169-183. 
118.  Zoogman S, Goldberg S, Hoyt W, Miller L. Mindfulness interventions with youth: A meta-
analysis. Mindfulness. 2014. 
119.  Mendelson T, Greenberg MT, Dariotis J, Gould L, Rhoades B, Leaf P. Feasibility and preliminary 
outcomes of a school-based mindfulness intervention for urban youth. Journal of Abnormal 
Child Psychology. 2010;38:985-994. 
120.  Huppert F, Johnson D. A controlled trial of mindfulness training in schools: The importance of 
practice for an  impact of well-being. Journal of Positive Psychology. 2010;5(4):264-274. 
121.  Tan L, Martin G. Taming the Adolescent Mind: Preliminary report of a mindfulness-based 
psychological intervention for adolescents with clinical heterogeneous mental health diagnoses. 
Clin Child Psychol Psychiatry. Dec 4 2012. 
122.  Baer RA, Lykins ELB, Peters JR. Mindfulness and self-compassion as predictors of psychological 
wellbeing in long-term meditators and matched nonmeditators. The Journal of Positive 
Psychology. 2012;7(3):230-238. 
Master Protocol 
S.M.A.R.T. Project Page 53 of 147  version 1.1  
01 March 2021 
 123.  MacBeth A, Gumley A. Exploring compassion: a meta-analysis of the association between self-
compassion and psychopathology. Clinical psychology review. Aug 2012;32(6):545-552. 
124.  Neff KD. The development and validation of a scale to measure self-compassion. Self Identity. 
2003;2:223-250. 
125.  Raes F. Rumination and worry as mediators of the relationship between self-compassion and 
depression and anxiety. Personality and Individual Differences. 2010;48(6):757-761. 
126.  Neff KD, Kirkpatrick K, Rude S. Self-compassion and its link to adaptive psychological functioning. 
Journal of Research in Personality. 2007;41:139-154. 
127.  Neff KD, Pi[INVESTIGATOR_105099] K, Hsieh YP. Self-Compassion and Self-Construal in the [LOCATION_002], 
Thailand, and Taiwan. Journal of Cross-Cultural Psychology. 2008;39(3):267-285. 
128.  Kuyken W, Watkins E, Holden E, et al. How does mindfulness-based cognitive therapy work? 
Behaviour research and therapy. 2010;48:1105-1112. 
129.  Van Dam NT, Sheppard SC, Forsyth JP, Earleywine M. Self-compassion is a better predictor than 
mindfulness of symptom severity and quality of life in mixed anxiety and depression. Journal of 
Anxiety Disorders. 2011;25(1):123-130. 
130.  Ying W-y. Contribution of self-compassion to competence and mental health in social work 
students. Journal of Social Work Education. 2009;45(2):309-323. 
131.  Roemer L, Lee JK, Salters-Pedneault K, Erisman SM, Orsillo SM, Mennin DS. Mindfulness and 
emotion regulation difficulties in generalized anxiety disorder: Preliminary evidence for 
independent and overlappi[INVESTIGATOR_105100]. Behavior therapy. 2009;40:142-154. 
132.  Gilbert P, McEwan K, Matos M, Rivis A. Fears of compassion: Development of three self-report 
measures. Psychology and Psychotherapy: Theory, Research and Practice. 2011;84(3):239-255. 
133.  Costa J, Pi[INVESTIGATOR_1946]-Gouveia J. Acceptance of pain, self-compassion and psychopathology: Using the 
chronic pain acceptance questionnaire to identify patients’ subgroups. Clinical Psychology and 
Psychotherapy. 2010. 
134.  Laithwaite H, O'Hanlon M, Collins P, et al. Recovery After Psychosis (RAP): a compassion focused 
programme for individuals residing in high security settings. Behavioural and cognitive 
psychotherapy. Oct 2009;37(5):511-526. 
135.  Joormann J, Dkane M, Gotlib IH. Adaptive and maladaptive components of rumination? 
Diagnostic specificity and relation to depressive biases. Behavior therapy. Sep 2006;37(3):269-
280. 
136.  Ciesla JA, Roberts JE. Rumination, negative cognition, and their interactive effects on depressed 
mood. Emotion. 2007;7(3):555-565. 
137.  Lo CC, Ho SM, Hollon SD. The effects of rumination and negative cognitive styles on depression: 
A mediation analysis. Behaviour Research and Therapy, . 2008;46:487-495. 
138.  Borkovec TD, Nau SD. Credibility of analogue therapy rationales.  J Behav Therap & Exp Psychiat. 
1972;3:257-260. 
Master Protocol 
S.M.A.R.T. Project Page 54 of 147  version 1.1  
01 March 2021 
 139.  Gotlib IH, Lewinsohn PM, Seeley JR. Symptoms versus a diagnosis of depression: Differences in 
psychosocial functioning. J Couns Psychol. 1995;63:90-100. 
140.  Inderbitzen HM. Adolescent peer social competence: A critical review of assessment 
methodologies and instruments. Advances in Clinical Child Psychology. 1994;16:227-259. 
141.  Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician 
Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, 
Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood 
disorders: a psychometric evaluation. Psychol Med. Jan 2004;34(1):73-82. 
142.  Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive 
symptomatology and the hamilton rating scale for depression: a sequenced treatment 
alternatives to relieve depression trial report. Biol Psychiatry. Mar 15 2006;59(6):493-501. 
143.  Moore HK, Hughes CW, Mundt JC, et al. A pi[INVESTIGATOR_105101], adolescent version of the 
quick inventory of depressive symptomatology. The Journal of clinical psychiatry. Sep 
2007;68(9):1436-1440. 
144.  Schaffer D. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): 
Description, differences from previous versions, and reliability of some common diagnoses. 
Journal of the American Academy of Child and Adolescent Psychiatry. 2000;39:28. 
145.  Angold A, Costello EJ, Messer SC. Development of a short questionnaire for use in 
epi[INVESTIGATOR_86523]. International Journal of 
Methods in Psychiatric Research. 1995;5:237-249. 
146.  Wood A, Kroll L, Moore A, Harrington R. Properties of the mood and feelings questionnaire in 
adolescent psychiatric outpatients: A research note. Journal of Child Psychology and Psychiatry. 
1995;36(2). 
147.  Daviss WB, Birmaher B, Melhem NA, Axelson DA, Michaels SM, Brent DA. Criterion validity of 
the Mood and Feelings Questionnaire for depressive epi[INVESTIGATOR_105102]-clinic subjects. 
Journal of child psychology and psychiatry, and allied disciplines. Sep 2006;47(9):927-934. 
148.  Hankin BL, Abramson LY. Measuring cognitive vulnerability to depression in adolescence: 
Reliability, validity, and gender differences. Journal of Clinical Child & Adolescent Psychology. 
2002;31(4):491-504. 
149.  Nolen-Hoeksema S, Morrow J. A prospective study of depression and posttraumatic stress 
symptoms after a natural disaster: the 1989 Loma Prieta Earthquake. J Pers Soc Psychol. Jul 
1991;61(1):115-121. 
150.  Nolen-Hoeksema S, Stice E, Wade E, Bohon C. Reciprocal relations between rumination and 
bulimic, substance abuse, and depressive symptoms in female adolescents. J Abnorm Psychol. 
Feb 2007;116(1):198-207. 
151.  Tangney JP, Wagner PE, Gavlas J, Gramzow R. The test of self-conscious affect for adolescents 
(TOSCA-A).  Fairfax, VA: George Mason University; 1991. 
Master Protocol 
S.M.A.R.T. Project Page 55 of 147  version 1.1  
01 March 2021 
 152.  Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. 
Journal of behavior therapy and experimental psychiatry. Jun 2000;31(2):73-86. 
153.  Arcury TA SA, Gesler WM, Dougherty MC. Diabetes beliefs among low-income, white residents 
of a rural North Carolina community. J Rural Health. 2005;21(4):337-345. 
154.  Arcury TA, Bell RA, Snively BM. Complementary and alternative medicine use as health self-
management: rural older adults with diabetes. J Gerontol B Psychol Sci Soc Sci. 2006;61(2):S62-
70. 
155.  Miles AM, Huberman MM. Qualitative Data Analysis: An Expanded Sourcebook.  2nd ed. 
Thousand Oaks, CA: Sage; 1994. 
Appendices 
A. Informed Consent Forms (Telephone consent, Parental Consent, Child Assent, Adult Consent) 
a. Telephone Consent 
b. Parental Consent  
c. Child Assent (ages 14-17) 
d. Adult Consent (age 18) 
B. Measures  
a. Quick Inventory of Depressive Symptomatology-Self-Report ( QIDS-SR)  
b. Diagnostic Interview Schedule for Children- Version IV (DISC-IV) 
c. Adolescent Survey 
i. Short Mood and Feelings Questionnaire (SMFQ-C) 
ii. Brief Resiliency Scale (BRS) 
iii. Adolescent Cognitive Style Questionnaire (ACSQ) 
iv. Ruminative Response Style scale – brooding factor (RRS-B) 
v. Test for Self-Conscious Affect for Adolescents (TOSCA-A) 
vi. Self-Compassion Scale (SCS)  
vii. Child and Adolescent Mindfulness Measure (CAMM) 
viii. Demographics   
d. Parent Survey 
i. Short Mood and Feelings Questionnaire (SMFQ-P) 
ii. Demographics 
e. PROMIS Pediatric Short Form (version 1.1)  
f. Expectation of Benefit / Credibility  
g. Daily Diary 
C. Recruitment Materials 
a. Flyer  
b. Email Announcement  
D. Data Safety Monitoring Plan (without Appendices)  
 
  
Master Protocol 
S.M.A.R.T. Project Page 56 of 147  version 1.1  
01 March 2021 
 Appendix A.a: Telephone Consent (version 0.3, 7 June 2017) 
 
  

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116745] Page 61 of 147  version 1.1  
01 March 2021 
 Appendix A.b: Parent Consent (version 0.3, 1 June 2017) 
 

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116746] Page 64 of 147  version 1.1  
01 March 2021 
 Appendix A.c: Child Assent (ages 14-17) (version 0.3, 1 June 2017)
 

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116747] Page 67 of 147  version 1.1  
01 March 2021 
 Appendix A.d: Adult Consent (version 0.3, 1 June 2017)
 

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116748] Page 70 of 147  version 1.1  
01 March 2021 
 Appendix B.a: QIDS-SR 
    
  

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116749] Page 74 of 147  version 1.1  
01 March 2021 
 Appendix B.b: Diagnostic Interview Schedule for Children- Version IV (DISC-IV) 
Only the Depression Section of DISC-IV shown. 
 
  

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116750] Page 102 of 147  version 1.1  
01 March 2021 
 Appendix B.c: Adolescent Survey Measures 
Short Mood and Feelings Questionnaire (SMFQ-C) 
 
  

Master Protocol 
S.M.A.R.T. Project Page 103 of 147  version 1.1  
01 March 2021 
 Brief Resiliency Scale (BRS) 
 

Master Protocol 
S.M.A.R.T. Project Page 104 of 147  version 1.1  
01 March 2021 
 Adolescent Cognitive Style Questionnaire (ACSQ) 
Questions 1, 2, 3, 6, 8, and [ADDRESS_116751] Page 110 of 147  version 1.1  
01 March 2021 
 Ruminative Response Style scale-brooding factor (RRS-B) 
Items 5, 10, 13, 15, [ADDRESS_116752] for Adolescents (TOSCA-A) 
 
  

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116753] Page 117 of 147  version 1.1  
01 March 2021 
 Self-Compassion Scale (SCS)  

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116754] Page 119 of 147  version 1.1  
01 March 2021 
 Child and Adolescent Mindfulness Measure (CAMM) 
  

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116755] Page 121 of 147  version 1.1  
01 March 2021 
 Appendix B.d: Parent Survey 
Short Mood and Feelings Questionnaire (SMFQ-P) 
 

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116756] Page 125 of 147  version 1.1  
01 March 2021 
 Appendix B.e: PROMIS Pediatric Short Form (version 1.1) 
Weekly measure for participants during 8-week intervention   

Master Protocol 
S.M.A.R.T. Project Page 126 of 147  version 1.1  
01 March 2021 
 Appendix B.f: Expectation of Benefit / Credibility  

Master Protocol 
S.M.A.R.T. Project Page 127 of 147  version 1.1  
01 March 2021 
 Appendix B.g: Daily Diary 
  

Master Protocol 
S.M.A.R.T. Project Page 128 of 147  version 1.1  
01 March 2021 
 Appendix IC: Recruitment 
Flyer 
 
 
  

Master Protocol 
S.M.A.R.T. Project Page [ADDRESS_116757] Page 130 of 147  version 1.1  
01 March 2021 
 Appendix IV: Data Safety Monitoring Plan (version 0.3, 23 May 2017) 
Appendices of Data Safety Monitoring Plan (DSMP) not included. The DSMP appendices include CVs for 
ISMC members, which goes from page 17-[ADDRESS_116758] Page 147 of 147  version 1.1  
01 March 2021 
  